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ABSTRACT 
 Iresine celosia L. is a traditional medicine used by the indigenous Mayan 
people for a variety of ailments. It is also the sole active ingredient in the 
Odyliresin™ formulation currently marketed to humans worldwide as an 
antioxidant and for the promotion of prostate health. However, Odyliresin™ has 
not been characterized phytochemically, or evaluated biologically for its intended 
use. This work represents the first comprehensive phytochemical investigation of 
the Odyliresin™ formulation botanical extract. To better understand its 
constitutive phytochemistry, a tailored isolation scheme was developed, using 
various chromatography resins (silica gel, LH-20), separation and purification 
techniques.   In all, eleven compounds were isolated from the extract. Relevant 
marker compounds were isolated and characterized using HR-MS, NMR, HPLC-
UV, FT-IR and CD spectroscopy. These marker compounds were then quantified, 
analytical methods developed, and analytical fingerprint profiles generated to 
standardize formulation extracts. Among the compounds isolated, a novel pair of 
cyclic guanidine alkaloids is reported. To our knowledge, this is the second 
reporting of 2-substituted imidazoline alkaloids isolated from a plant source. 
These compounds were screened in silico for their ability to bind to the human 
androgen receptor (AR), a target for anti-androgen prostate cancer therapies, and 
further tested for their biological activity in AR-positive (LNCaP) and AR-
negative (PC3) prostate cancer cell lines. These compounds show activity against 
AR-positive LNCaP cells in the 12.5-50 µM range, while AR-negative PC3 cells 
were unaffected. In addition, compounds isolated from Iresine celosia L. were 
screened using drug metabolism and toxicology simulation studies in silico, to 
predict the formation of reactive metabolites and their possible toxicological 
 endpoints using Simulation’s Plus ADMET Predictor proprietary software. The 
isolation and structure elucidation of eleven compounds from the formulation, two 
of which are new, the development of analytical methods to quantify their 
presence within the extract, and initial in silico toxicology screening offer 
information that can be used to support a level of quality production and a 
reasonable expectation of safety when using this dietary supplement as directed 
for the promotion of prostate health. 
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 1 
1. Natural Products: History and What it Has Become 
 The timeless use of plants as medicine by man was formally christened a 
Western science by the German C.A. Seydler in his 1815 thesis and book, 
Analecta Pharmacognistica. Combining the Greek words for “drug” (φάρµακον, 
pharmakon), and the verb “to know, to discover,” (γιγνώσκω, gignosko), he 
coined the phrase pharmacognosy to describe the scientific field that deals with 
the chemistry, biological activity, and biosynthesis of natural products, or 
secondary metabolites.  
 The use of these specific Greek words remains to this day a fitting choice, as 
pharmacognosy continues to be primarily a discipline of drug discovery [1]. The 
discovery of pharmacological agents from natural sources or based on natural 
pharmacophores was made possible by advancements in separation science. 
Seydler’s treatise was published at a time when new methods resulting from the 
rise of industrial expansion in Britain, western Europe and the United States in the 
19th century allowed for the manufacture of fine chemicals, including the isolation 
of medicinal substances from plants, such as quinine, camphor and ether, 
ingredients employed in the pharmacy of the day [2]. This included advancements 
in the large-scale extraction of drugs from plant material by means of solvents, 
usually water or alcohol, which was still a function of the pharmaceutical 
manufacturer at the end of the 19th century [3].  
 By the early years of the 20th century, researchers had indicated that the 
action of “vegetable drugs” was due to the presence of definite chemical 
compounds, many of which had been isolated already. Among them were certain 
alkaloids, notably quinine and morphine. The isolation of these active compounds 
 2 
in a pure state had far-reaching consequences in medicine and in the industry of 
fine chemicals. For one, more accurate dosing for the drugs of that time became 
possible; it is important to appreciate that this had previously been impossible, as 
patients were treated with crude drugs of unknown or variable composition. 
Secondly, harmful effects due to the presence of impurities in the crude drugs 
could be mitigated or avoided and a level of quality control of the formulated dose 
could be achieved [4]. In the case of quinine, its isolation from Cinchona bark in 
1820 by Pelletier and Caventou revolutionized the treatment of malaria, as it was 
possible to give a measured dose of the pure alkaloid compound instead of the 
nauseous bitter brews that had been the prescription since the 1630s. Thirdly, 
investigation of the chemical composition of the active principles was possible. 
Among other advancements, this third point led to the development of synthetic 
organic chemistry, which aimed to synthesize active principles and related 
substances. The advent of synthetic products, however, did not diminish the large-
scale extraction of drugs from plant material by means of solvents, usually water 
or alcohol. At the beginning of the 20th century, preparation of plant materials 
comprised about half of medicines in the United States Pharmacopeia [5]. 
 To this day, natural products and structures derived from natural products 
continue to play a vital role in the therapeutic armament [6]. Centuries of co-
evolution have taken place between organisms that produce these compounds 
(thought by some to be produced by the organism for the purposes of protection, 
to ward off predators, harmful effects of UV rays, or as a strategy to be more 
widely cultivated, by pollinators or cultivators like humans, for example), and 
those that use them for medicines. Therefore, it is not surprising that natural 
product structures offer leads of higher quality than mass efforts to synthesize 
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bioactive compounds. Natural product secondary metabolites have been honed for 
biological function. 
 For the most part, formal research in the area of natural products chemistry 
has continued to take the approach to isolate and extract single active ingredients, 
to search for “silver bullet”-type molecules that may go on to be used as 
pharmaceutical-like medicines. Some have made attempts to understand the 
synergistic function of active ingredients [7, 8]. These “active principles” from 
natural sources can be of great value in the search for bioactive molecules because 
they often possess intricate architecture, with more stereogenic centers and chiral 
complexity than can be synthesized in a lab. For these reasons, as well as their 
coevolution among living systems, natural products have been the single most 
productive source of leads for the development of drugs, and the source of most of 
the active ingredients of medicines. 
 Emphasis on isolation of single active principles has resulted in natural 
products being evaluated, both for efficacy and safety, under a pharmaceutical and 
food additive-type paradigm [9]. That scientific paradigm for the evaluation of 
natural products in commercial use, in the form of dietary supplements, is outlined 
in the 2011 Draft New Dietary Ingredient Guidance document, which is discussed 
in detail elsewhere in this work (see Chapter 4). The historical and ethnobotanical 
uses of herbs have given way to evaluation and testing of dietary supplements, 
mostly through the isolation of single active principles. As mentioned above, this 
has allowed for desirable outcomes, like more accurate dosing, quantification, and 
specifications for formulation and its testing. However, it is important to keep in 
mind that the reduction of complex botanical mixtures down to single active 
principles is a model in itself that simplifies at the outset. Nevertheless, the 
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reduction of the action of an herbal medicine to individual active principles makes 
possible their pharmacological and toxicological evaluation. Toxicology and 
pharmacology, sciences that have been built on the evaluation of single active 
ingredient pharmaceutical compounds and environmental toxins, is now being 
applied to the evaluation of herbal medicines. 
 However, even when reduced to single active principles, natural products 
differ structurally, in their activity, and in their modes of action from these types 
of chemicals. In general, these compounds tend to differ from synthesized 
pharmaceutical compounds in the structural features that they employ. Natural 
products possess exceptional chemical functionality that keep them compatible 
with the aqueous milieu of biological microenvironments [10]. Nature often 
exploits reactive functional groups in biologically active natural products. Natural 
products typically have more stereogenic centers, and are more architecturally 
complex than synthetic molecules. Natural products contain relatively more 
carbon, hydrogen, and oxygen, and less nitrogenated or other elements than 
synthetic agents. Synthetic medicinal chemistry prefers a high proportion of 
aromatic and heteroaromatic rings, fewer stereogenic centers, lower molecular 
weights, lipid-soluble molecules, with a lack of chemical reactivity. Natural 
products tend to be more polar, water soluble, and adaptable to fluctuations in pH. 
 Furthermore, single active principles isolated from botanicals that are not 
necessarily developed and consumed primarily by humans as drug molecules, but 
that are consumed primarily as one of many phytochemical constituents within 
dietary supplement formulations in relatively minute quantity as compared with 
pharmaceutical prescription dosing, present a different pharmacological profile 
altogether. Standardization of extracts can reveal that what are thought to be the 
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active ingredients are present in very small quantities, on the microgram, 
nanogram and picogram scale – concentrations that may be well below a threshold 
needed to see a toxic effect. While most of these single active principles within 
the context of their use in a botanical dietary supplements can be considered safe, 
there exist a few compounds that can be considered toxic.  
 When considered as a whole, these compounds tend to exert toxic effects 
through oxidative metabolism into biologically reactive intermediates (BRIs) [11-
14]. When dosed properly, these compounds can also be found to exert chemo-
preventive effects. The overall risk/benefit of botanical dietary supplements can 
be thought of as the result of BRI formation and interaction with resulting 
biological targets, which likely depends on the level of reactivity and selectivity of 
the BRI, as well as the dose and time of exposure. 
 Biotransformation of a compound into reactive metabolites is largely a 
function of its chemical properties. The presence of certain chemical functional 
groups has been associated with toxicity due to the formation of reactive 
metabolites. Phytochemicals containing structural features like conjugated 
systems, simple Michael acceptors, epoxides, carbocations, quinoids, terminal 
alkenes, acetylenes, and benzodioxoles, among others, or the ability to form them, 
have been commonly associated with reactive metabolite-mediated adverse effects 
in botanical dietary supplements [12-15]. For decades, structural alerts have also 
been used to mitigate toxic liabilities for pharmaceuticals, environmental 
chemicals, and food additives, though the structural features present in these 
classes of compounds tend to differ from those associated with botanical natural 
products [11, 16-20]. Mitigating metabolism-related liabilities for pharmaceuticals 
and environmental toxins is often accomplished through in silico screening of 
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compounds for these structural alerts. This strategy has been used successfully 
both by manufacturers and regulators of these products, who find these 
computational SAR toxicology models to be both reasonably sensitive and 
specific [17, 18, 21-25]. A similar methodology could be applied to mitigate risk 
from dietary supplements, but such an approach should be specific to the risks 
presented by the particular chemistry of natural products. 
 The benefit of this approach is a substantial reduction, replacement, and 
refinement in the need for biological and particularly animal toxicological testing 
required to establish the safety of chemical substances. Within the food additive 
regulatory paradigm, screening for structural alerts also allows for the 
development of thresholds of concern, which then trigger requirements for further 
testing before the product can be introduced to the marketplace. If similar 
structural alert screening could be conducted for dietary supplements, and 
threshold of concern regarding a dietary supplement’s risk profile could be 
determined, the extensive, resource intensive, and costly testing outlined within 
the New Dietary Ingredient Draft Guidance of 2011 may not be entirely necessary 
for every phytochemical ingredient present in every natural product brought to 
market. 
 When combined with phytochemical characterization and standardization, 
such an approach may help to mitigate the health risks posed by botanical dietary 
supplements. The work that follows attempts to apply such an approach to the 
evaluation on one of the nearly one thousand new dietary supplements brought to 
market each year. 
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2. Justification for and Significance of the Study 
 The use of natural product medicine in the form of dietary supplements in 
the U.S. has increased significantly over the past two decades [26]. Since the 
passage of the Dietary Supplement Health and Education Act (DSHEA) in 1994, 
the botanical dietary supplement market in the US has grown from $2.9 billion in 
1995 to $4.8 billion in 2008 [27, 28]. It is estimated that over one thousand new 
dietary supplement products entering the market each year [29]. For the natural 
products chemist, this trend translates into new challenges to evaluate the quality 
of botanical ingredients, which is linked directly to the safety and efficacy of the 
final dietary supplement product. 
 For all their popularity, however, many commercial botanical products are 
poorly defined scientifically. In the United States, consumers take it on faith that 
the supplement they are ingesting is the same as is listed on the label, and that it 
contains the reportedly “active” constituents they seek [30]. While a number of 
commonly used herbs are generally regarded as safe (GRAS), many herbs that 
have been in use for centuries as traditional medicines are not necessarily 
guaranteed to be either safe for consumption or efficacious, in part due to a lack of 
scientific investigation. In the words of the Institute of Medicine, “the same 
principles and standards of evidence of treatment effectiveness apply to all 
treatments, whether currently labeled as conventional medicine or [as] 
complementary and alternative medicine (CAM)” [31, 32]. Whether botanical or 
synthetically derived, medicines should be made in a safe and reproducible 
manner, with an understanding of the degree of efficacy related to the medicine’s 
intended use. The study goes on to explain that in the case of CAM, “safety 
trumps efficacy”, and “the absence of evidence of effectiveness does not imply 
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absence of effectiveness” [29]. Whether or not clear evidence of effectiveness for 
a given condition is found, these therapies can and should be scientifically 
investigated, for their safety as well as for the presence of known and/or novel 
phytochemicals present that may possess biological activity. 
 Odyliresin™ is a botanical supplement formulation currently marketed to 
humans for the promotion of prostate health [33]. The tincture is comprised of a 
30% ethanol extract of the botanical Iresine celosia. The plant is a member of the 
Amaranthaceae family and goes by several botanical synonyms and common 
names, as listed in Table 1 [34-38]. 
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Table 1: Botanical Synonyms and Common Names for Iresine 
celosia[34-38] 
Taxonomical synonym for Iresine celosia L. Common names 
Iresine diffusa 
Humb. & Bonpl. ex Willd. 
Juba bush 
Bloodleaf, Camarón, shrimp 
plant, hierba de la plata (silver 
herb, Central America), 
plumaria (little feather, 
Columbia), velo de princessa 
(princess’s veil, Guatemala), 
nerve wist 
Iresine canescens  
Humb. & Bonpl. ex Willd 
 
Iresine celosioides (L.) tlatlancuaya 
Iresine chalk tlatlancuaya 
Iresine elongata  
Humb. & Bonpl. ex Willd 
 
Iresine paniculata (L.)  
Kuntze, non Poir 
 
Iresine flavescens 
Humb. & Bonpl. ex Willd 
 
Iresine gracilis 
Humb. & Bonpl. ex Willd 
 
Alternanthera flavescens 
Humb. & Bonpl. ex Willd 
 
Iresine calea (Ibftenz)  
Iresine latifolia  
Gomphrena latifolia  
Iresine laxa Amargosilio, tepozan, erba del 
tabardluo herba de la calenture; 
mosqultero; clacancauayo 
(derived from the Nahuatl 
tlatiancua-ye “which has knees,” 
referring to jointed stems) 
Alternanthera paniculata  
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 The plant is native to the Southeastern United States, Mexico, Central and 
South America, and the West Indies. It has a history of use by indigenous peoples, 
including the Highland Mayans of Chiapas, Mexico, who referred to the plant as 
tlatlancuaya [39]. A variety of anecdotal indications accompany the plant, 
including its ancient use for the treatment of skin conditions such as dropsy, 
reproductive health, gonorrhea and malaria [40]. The plant is also one of several 
ingredients included in Jamaican root tonics for male virility and overall health, 
among other varied indications [35, 36, 41-43]. The Odyliresin™ formulation of 
Iresine celosia has been marketed as a treatment of tumorigenic conditions at 
large and for epilepsy as far back as 1965, and more recently as an antioxidant 
[44].  
 Previous phytochemical analysis may have been conducted on the plant 
under one of the plant’s many botanical synonyms. Using classic techniques for 
the isolation and elucidation of phytochemicals, Djerassi and his colleague Pierre 
Crabbé reported two main chemical constituents of the plant. The first was the 
then unknown drimane iresin, reported in 1953, which took six years to elucidate 
its structure [39, 45-49]. Its spectral assignment was not reported until 2005 in a 
paper that also identified the presence of the previously reported compounds 
triacontanol, beta-sitosterol, stigmasterol, alpha-amyrin-3-O-beta-D-
glucopyranoside, beta-amyrin-3-O-beta-D-glucopyranoside, beta-sitosteryl-beta-
O-D-glucopyranoside and iresin [50]. The 2005 paper by Rios and colleagues also 
identified three new drimanes from the plant: 3,14-dihydroxy-17,8-drimen-11,12-
acetonide; 3,7,14-trihidroxy-18,9-drimen-11,12-olide; and 3,7,14-trihydroxy-18,9-
drimen-11,12-olide. The 2005 Rios paper did not report a second compound 
isolated by Djerassi and Crabbé, tlatlancuayin, or 2',5-dimethoxy-6,7-
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[methylenebis(oxy)]isoflavone;2',5-Dimethoxy-6,7 methylenedioxyisoflavone 
[48]. The drimane structures, along with iresin and isoflavone tlatlancuayin, are 
listed in Table 2 and Figure 1. However, it is not clear that these plants were 
definitively identified as Iresine celosia. 
 This work represents the first phytochemical evaluation of the Iresine 
celosia herbal supplement formulation.  
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Table 2: Compounds Isolated from Iresine diffusa 
 
Compounds Isolated From Iresine diffusa 
iresin 
tlatancuayin 
3-beta,7-alpha,14-trihydroxy-delta-8,9-drimen-11,12-olide 
3-beta,7-beta,14-trihidroxy-delta-8,9-drimen-11,12-olide 
3-beta,14-dihydroxy-delta-7,8-drimen-11,12-acetonide 
dimethoxy-6,7-[methylenebis(oxy)]isoflavone;2',5-Dimethoxy-
6,7 methylenedioxyisoflavone 
triacontanol 
beta-sitosterol 
stigmasterol 
alpha-amyrin-3-O-beta-D-glucopyranoside 
beta-amyrin-3-O-beta-D-glucopyranoside 
beta-sitosteryl-beta-O-D-glucopyranoside      
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Figure 1: Structures of Chemical Constituents Identified in Iresine 
diffusa 
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3. Aims of This Work 
 The work set out to evaluate the quality, safety and efficacy of the dietary 
supplement Odyliresin™ formulation of the botanical Iresine celosia through the 
following aims: 
• Aim 1: Ensure quality through biological classification of plant 
starting material, the isolation and characterization of known and/or 
novel chemical constituents of the Iresine celosia extract, and the 
development of methodologies for preparation where needed. 
• Aim 2: Evaluate the safety of isolated phytochemicals using in silico 
drug metabolism and toxicology simulation studies, to predict possible 
metabolites generated in vivo and their possible toxicological 
endpoints using ADMET predictor proprietary software. 
• Aim 3: Biological investigation using in-house bioassays and in silico 
molecular docking experiments with targets involved in prostate 
cancer, with a focus on the human androgen receptor. 
 
4.  Outline of Chapters 
 Chapter 1 set a backdrop for the history and current conditions under which 
the present study is being conducted. We set out our aim of investigating 
phytochemically a traditional herbal medicine made dietary supplement, currently 
used in humans to promote prostate health. 
 Chapter 2 goes into detail describing the isolation and structural elucidation 
of 11 compounds from the Iresine celosia Odyliresin™ formulation extract, with 
the reporting of two new and structurally rare (see Table 3) guanidine alkaloids 
that show activity as possible androgen receptor (AR)-binders in silico, and inhibit 
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growth of AR-dependent prostate cancer cells. Until now, guanidine alkaloids 
have not been found in Iresine celosia. 
 
Table 3: Plant Species Known to Contain Guanidine 
Alkaloids 
 
Order Family Genus, species 
Asterales Asteraceae Verbesina peraffinis 
Caryophyllales Plumbaginaceae Plumbago zeylania 
Fabales Fabaceae Canavalia rosea 
Fabales Fabaceae Milletia laurentii 
Fabales Fabaceae Psterogyne nitens 
Malpighiales Eupgorbiaceae Alchornea cordifolia 
Ranunculales Ranunculaceae Cimicifuga racemosa 
Solanales Solanaceae Solanum cernuum 
 
 
 Chapter 3 outlines a method for the HPLC-analysis and the calibration of 
these two new, species-specific compounds as analytical standards to identify the 
extract chemically, as well as an analytical fingerprint profile to which a crude 
chromatogram can be compared. Chapter 3 also allows for understanding of 
concentrations of these compounds in dosing of the supplement in its current 
formulation. 
 Chapter 4 discusses current regulatory environment calling for more 
stringent testing of botanicals for the evaluation of their safety and risk, a 
perspective on the proper evaluation of risks presented by phytochemicals used as 
medicine, and how in silico ADME/Tox screening can be applied to the safety 
evaluation by regulators and manufacturers of botanical dietary supplements, as it 
has been for food additives, environmental toxins, and pharmaceuticals. This 
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strategy offers an opportunity for cost-savings, and reduced and conscientious use 
of animal testing,   
 Chapter 5 evaluates the ability of these compounds to form reactive 
metabolites, the ability of parent compounds and metabolites to cause CYP 
enzyme inhibition, and for other structural features that may be related to toxic 
liabilities. This is accomplished through the use of Simulation’s Plus ADMET 
Predictor software designed for ADME/TOX (PK) screening. 
 At the end of this work, it is hoped that perspective on the chemistry, 
biological activity, and potential risk profile of this particular botanical 
formulation is gained, through the understanding of pharmacognosy. 
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Abstract: Among eleven compounds isolated from the plant, two new, 
structurally rare cyclic guanidine alkaloids have been isolated and characterized 
from the aerial portion of Iresine celosia. The structures of 1 and 2, celosiadine A 
and B, were confirmed by 1D and 2D NMR spectroscopy as well as HRESIMS. 
Since a commercial formulation of the botanical is currently consumed by humans 
for the purpose of promoting prostate health, compounds isolated from the plant 
were screened in silico for their ability to bind to the human androgen receptor 
(AR). Compounds 1 and 2 showed favorable binding affinity (-6.6 and -6.8 
kcal/mol respectively) in wild type AR and mutant AR T877A and H874Y crystal 
structures that were then evaluated for their activity in vitro against androgen-
independent prostate cancer cell line PC3, and the androgen-sensitive prostate 
adenocarcinoma cell line LNCaP. Preliminary in vitro work confirmed findings 
from the in silico docking experiments. Statistically significant changes were 
observed in LNCaP cells following 24 hour exposure at concentrations ranging 
from 12.5 - 50 µM were observed, while PC3 cells remained almost entirely 
unaffected by the compounds, suggesting that the compounds isolated from this 
formulation could have therapeutic implications in androgen-dependent prostate 
cancers. 
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Introduction: 
 For centuries in Asia, Africa and India, phytotherapy has been considered 
a first line treatment for conditions of the prostate, and in the United States and 
Europe, the number of people using medicinal plants for prostate related 
conditions, including prostate cancer, has been on the rise [1]. Iresine celosia, a 
member of the family Amaranthaceae, is native to the Southeastern United States, 
Mexico, Central and South America, and the West Indies. The plant has 14 or 
more botanical synonyms [2-5], and has been previously investigated for its 
phytochemistry under the name Iresine celosiodies [6-11], and more recently 
under the name Iresine diffusa [12]. It has a history of use as a remedy by 
indigenous peoples, including the Highland Mayans of Chiapas Mexico, who 
referred to the plant as tlatlancuaya [9]. A variety of anecdotal indications 
accompany the traditional use of the plant, including those for skin conditions like 
dropsy, gonorrhea and malaria. A formulation of the aerial portions of the plant 
was developed in the 1960s and has since been promoted for a variety of 
applications, including epilepsy, as an antioxidant, and for promoting health in 
tumorigenic conditions at large, especially of the prostate [33]. This formulation, 
comprised of a 30% ethanol extract of the aerial portions of the plant, is currently 
consumed by humans. However, the chemical constituents of this formulation are 
not known. Herein, the isolation and structure elucidation of two new guanidine 
alkaloids, celosiadine A and B (1, 2), along with the purification of 
hydroxygalegine (3), and eight other compounds from the formulation and aerial 
portions of the plant are reported (Fig. 2).  
 As a class, guanidine compounds are relatively rare as secondary 
metabolites, and are found more commonly in marine sponges than in higher 
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plants. They posses a wide range of biological activity and impressive chemical 
structures [13, 14]. To our knowledge, this is the first reporting of guanidine 
alkaloids in the Amaranthaceae family, the second reporting within the 
Caryophyllales order, and the second ever reporting of cyclic guanidine alkaloids 
isolated from a plant source [15]. Cyclic guanidine alkaloids have been found as 
the products of secondary metabolism in sponges. Sponge-derived guanidine 
alkaloids, and imidazoles in particular, are well known for their anti-cancer 
properties [16]. Thus, as the formulation is used for promoting health in 
tumorigenic conditions, especially that of the prostate, further biological 
experiments were conducted to evaluate the therapeutic potential of the 
compounds. 
 In silico docking experiments have previously helped to elucidate the anti-
cancer activity of plant natural product compounds against prostate cancer cell 
lines expressing the T877A mutation [17, 18]. Small molecule plant natural 
products like epigallocatechin gallate from green tea (Camellia sinensis) and 
atraric acid from Pygeum africanum have been found to act as anti-androgens, 
both active at an in vitro concentration of 10 µM. In particular, atraric acid has 
demonstrated the ability to inhibit transport of the AR to the nucleus, and has been 
shown to efficiently repress the growth of androgen-dependent LNCaP prostate 
cancer cells, but not androgen-independent cell lines, like PC3 [19]. Therefore, to 
test whether compounds isolated from Iresine celosia could act in a similar 
fashion, Compounds 1 and 2 were screened in silico for their ability to bind the 
androgen receptor crystal structures for both wild type and prostate cancer-related 
mutants. 
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 Compounds 1 and 2 were screened in silico for their ability to bind to the 
crystal structures of AR wild type (PDB ID: 2YHD), and two mutant varieties 
relevant to the progression of prostate cancer with crystal structures available in 
the Protein Databank, T887A (PDB ID: 1I37) and H874Y (PDB ID: 2Q7K) [20, 
21]. Binding affinities resulting from docking experiments were compared with 
the AR's natural ligands, testosterone and dihydrotestosterone (DHT), known non-
AR binders beta-sitosterol and stigmaterol, known AR-binding small molecule 
natural products EGCG and atraric acid, and compounds implicated in BPH-
related prostate health: apigenin, emodin, baicalein, genistein, icaritin, 
xanthohumol (see Tables 7-9) [22]. The lab constituted Iresine celosia 
formulation extract, and pure Compounds 1 and 2, were then evaluated for their 
ability to inhibit prostate cancer cell growth as compared to control, using LNCaP 
prostate cancer cells, that express the AR mutant T877A, and PC3 AR-
independent cell lines. 
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Figure 2: Structures of Compounds Isolated from Iresine celosia 
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Results and Discussion: 
 In total, eleven compounds were isolated from Iresine celosia (Fig. 2). 
Alongside two novel cyclic guanidine alkaloids, celosiadine A and B, compounds 
(1) (25 mg) and (2) (5.7 mg) respectively, a third known guanidine containing 
alkaloid, hydroxygalegine, was isolated, compound (3) (2.3 mg). The 30% ethanol 
extract of the plant also posses a number of nucleosides, among them, 2’deoxy-
uridine (7) (3.5 mg), 2’deoxy-thymidine (8) (13 mg), uracil (4) (0.7 mg) and 
adenine (5) (2.8 mg), along with some additional small molecule structures, 3-
indole-carboxyllic acid (6) (2.8 mg), anisic acid (10) (1.8 mg), and 
phenylacetamide (11) (3 mg). The identity of these structures was assigned based 
on analysis of the 1H spectra and the 13C NMR spectra and in accord with 
assigned values from the literature. 
 
  Biosynthesis 
 The biosynthesis of the two new compounds, celosiadine A and B, could 
be explained by the isolation of a third, known compound whose biosynthesis has 
been investigated through the use of radiolabeled feeding experiments. Alongside 
celosiadine A and B, or compounds (1) and (2) respectively, 4-hydroxygalegine 
(3) was also isolated. Its parent compound galegine (1-guanidino-3-methyl-2-
butene) is a guanidine derivative found together with hydroxygalegine in the seeds 
of Goat’s Rue, Galega officinalis. Galegine is synthesized in the shoot of the plant 
and is found to accumulate in the seeds. Surprisingly, its isoprenoid hydrocarbon 
chain does not arise from the mevalonic acid-isopentenyl pyrophosphate sequence 
of terpenoid biosynthesis. Rather, a series of radiolabeling experiments conducted 
between 1965-1968 by Reuter et al. showed that the guanidino group is added by 
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a transamidation of an amidino group of arginine [23-26]. More specifically, 14C-
radiolabeled arginine and its biosynthetic precursor, ornithine, were both applied 
to young seedlings of Galega officinalis. Pyruvate was found to be a precursor of 
the galegine compound, but mevalonic acid was poorly incorporated. Later, when 
14C-amidino labeled guanidino-acetic acid hydrochloride was added to seedlings 
of Galega officinalis, 90% of radioactivity was found in the amidino group of 
galegine, suggesting that guanidine-acetic acid is the biosynthetic precursor of 
galegine. Thus, it is likely that related compounds 1 and 2 are biosynthesized in a 
similar manner (see Figure 4). 
  A simple rearrangement of the hydroxygalegine molecule could allow for 
a cyclization of the compound between the double bond and the free amine. 
Double bond isomerization could account for the imidazoline ring. The primary 
alcohol at the end of the alkyl chain off of the now cyclized imidazoline ring 
could be oxidized to form a carboxylic acid. Condensation of the cyclized 
compound with the alkyl moiety of an additional guanidinoacetic acid molecule 
could be responsible for the additional side chain seen in Celosiadine B. 
Nucleophilic attack of an alcohol group from water results in the alkene 
isomerization of the double bond into the terminal alkene seen in Celosiadine A.  
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Figure 4. Proposed biosynthesis of Celosiadine A and B from 
Hydroxygalegine  
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Spectral Analysis 
 Compound (1), 2-[2-Amino-1-(2-hydroxy-3-methyl-3-butenyl)-4-
imidazolinyl]propionic acid, a light yellow amorphous solid, was assigned the 
name Celosiadine A, and assigned the formula C11H19N3O3 based on HRESIMS 
data at m/z 242.1500 [M+H]+  (calcd C11H19N3O3, for 242.1499). The IR 
absorptions revealed the presence of peaks at 3380 cm-1 and 1700 cm-1, indicating 
the carboxylic acid functionality; a broad band (3400-2000 cm-1) indicated N-H, 
and an additional band at 1600 cm-1 supported the presence of the guanido group.  
 Detailed analysis of the 1D and 2D NMR (1H-1H COSY, HSQC, HMBC) 
data allowed for the construction of the structure of Compound (1). The 1H and 
the 13C NMR spectra (Table 4) characteristic of a guanidine moiety (δC 158.75), a 
carboxylic acid group (δC 175.60), a quaternary carbon (δC 145.93) of a terminal 
vinyl group (δC 112.16), also indicated by the presence of two singlets at 5.07 and 
4.93 (H-1) that integrated for one proton each. In addition, two methyls, two other 
methylenes, and three methines were detected. 
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Table 4. Spectral Assignments for Compound (1) 
 
Position δ C (mult.) δ H (mult., J in 
Hz) 
COSY HMBC  
1 112.16, 2H 5.07, 4.93, s H-3, H-5 C-5, C-3 
2 145.93   H-5, H-4, H3, H1 
3 71.29, 1H 4.22, dd (7.8, 3.9) H-1, H-4  C-5, C-4, C-2, C-1 
4 48.70, 2H 3.42, dd (15.1, 3.9) H-3 C-3, C-2, C-4’, C-3”, C-
2” 
  3.38, dd (15.1, 7.8) H-3 C-3, C-2, C-4’, C-3”, C-
2” 
5 18.67, 3H 1.77, s H-1, H-3 C-3, C-1 
6  8.42, s   
3'  7.87, s   
4' 158.75   H-4, H-4”, H-3” 
1" 12.92, 3H 1.18, d (7.8) H-2” C-5”, C-3”, C-2” 
2" 43.79, 1H 2.59, m H-3”, H-1” C-5”. C-3”, C-1” 
3" 54.54, 1H 4.11, m (10.1, 6.6) H-4”, H-2” C-5”, C-4”, C-2”, C-1” 
4" 52.60, 2H 3.92, dd (10.1) H-3” C-4’, C-3”, C-2” 
  3.55, dd (10.1, 6.6) H-3” C-4’, C-3”, C-2” 
5” 175.60    
6"  12.51, s   
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 There were 1H−1H COSY correlations between H-5/H-1/H-3/H-4, and 
between H-4"/H-3"/H-2"/H-1".  In the HMBC spectrum, the guanidine carbon 
signal at δC 158.75 showed correlations with protons δH 3.92 and 3.55 (H-4), and 
δH 3.42 and 3.38 (H-4"), and δH 4.11(H-3"). The carboxylic acid group at δC 
175.60 had correlations with protons δH 4.11(H-3") 2.59 (H-2") and 1.18 (H-1"). 
The quaternary carbon at δC 145.93 correlated with protons δH 5.07 and 4.93 (H-
1), δH 4.22 (H-3), 3.42 and 3.38 (H-4), and δH 1.77 (H-5). The terminal alkene at 
δC 112.16 was shown to correlate with protons δH 4.22 (H-3) and 1.77 (H-5). Also, 
the carbon at the secondary alcohol, δC 71.29, revealed correlations with protons 
δH 5.07 and 4.93 (H1), and 3.42 and 3.38 (H-4). For key HMBC (H→C) and 
1H−1H COSY correlations, see Figure 3.  
 The relative configuration of stereocenters at C-3" and C-2" was 
determined by 1D and 2D NOESY experiments, with emphasis on couplings at 
protons C-4" to protons at these stereocenters (see Figure 14-15). The proton H-4" 
at δH 3.92 showed the effect of being coupled to H-3" at δH 4.11, while proton H-
4" at δH 3.57 showed the effect of being coupled to the H-2" at δH 1.18. This 
information provided information about the relative configuration of these protons 
with respect to each other, but could not be extrapolated to provide information on 
the absolute stereochemistry of these stereocenters. In addition, the proton H-1 at 
δH 4.93 was found to be coupled to H-5 at δH 1.77, while H-1 at δH 4.93 was 
coupled to H-3 at δH 4.22, providing further confirmation of the assignment of the 
terminal alkene to its position on the alkyl chain substituent branching off from 
the imidazoline ring. 
  Chiral derivatization of the stereocenter at the secondary alcohol present 
at C-3 using Mosher’s esterification failed, perhaps due to the conformational 
flexibility and rotatability of both the imidazoline ring’s side chains. With three 
stereocenters, eight stereoisomers are possible, and it is possible that all eight may 
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be present when isolated from the crude botanical mixture. Attempts to crystalize 
the compound were also unsuccessful. To resolve the absolute configuration of 
stereocenters present within Compound (1), theoretical calculation of electronic 
circular dichroism (ECD) by time-dependent density functional theory (TDDFT) 
will be used. This method has previously been used to determine the absolute 
configuration of highly flexible compounds, including alkaloids, as well as other 
conformationally rigid natural product molecules [51]. 
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Figure 3. Key 1H -> 1H COSY (bold lines) and HMBC (H->C) 
(arrows) Correlations for Compound (1) 
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Table 5. Spectral Assignments for Compound (2) 
 
Position δ C (mult.) δ H (mult., J in 
Hz) 
COSY HMBC  
1 18.17, 3H 1.73, s H-4 C-5, C-3, C-2 
2 138.45   H-5, H-4, H-1 
3 117.42    H-5, H-4, H-1 
4 41.87, 2H 3.95, dd (7.1) H-6, H-1 C-3, C-2, C-4’, C-4” 
5 25.86, 3H 1.79, s H-4 C-3, C-2, C-1 
6  5.18, t (7.1) H-4 C-5, C-1 
3'  8.05, s   
4' 159.14   H-4, H-4” 
1" 12.87, 3H 1.14, d (7.1) H-2” C-5”, C-3”, C-2” 
2" 43.73, 1H 2.56, m H-3”, H-1” C-5”. C-3”, C-1” 
3" 54.53, 1H 4.11, m (10.1, 6.3) H-4”, H-2” C-5”, C-4”, C-1” 
4" 50.88, 2H 3.72, dd (10.1) H-4”, H-3” C-3”, C-2” 
  3.36, dd (10.1, 6.3) H-4”, H-3” C-3”, C-2” 
5” 175.59   H-2”, H-1” 
6"  12.69, s   
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 Compound (2), 2-[2-Amino-1-(3-methyl-2-butenyl)-4-
imidazolinyl]propionic acid, a light yellow powder, is chemically related to 
compound 1, with a molecular formula of C11H19N3O2 as determined by 
HRESIMS at m/z 226.1547, [M+H]+  (calcd for C11H19N3O2,  226.155). The 
NMR chemical shifts of compound (2), presented in Table 5, were similar to that 
of Compound (1), except for differences in the carbon chemical shifts of C-1 (δC 
18.17) and C-3 (δC 117.42), reflecting a change in the placement of the double 
bond between the two compounds. The IR spectrum of Compound (2) was similar 
to Compound (1), in that it revealed the presence of peaks at (3500-3350) and 
1700, indicating the carboxylic acid functionality; 3400-2000 broad indicated N-
H, and an additional band at 1600 supported the presence of the guanido group, 
with slight variation with the peak at 1000 cm-1 more pronounced in compound 
(2) than in the fingerprint region from its related compound (1).  
 The structure of compound (3), hydroxygalegine, was determined through 
analysis of the 1D and 2D NMR experiments (see Table 6) and comparison with 
the literature [27]. The isolation of this compound helped to support rationale for 
the proposed biosynthesis of compounds (1) and (2) as deriving from arginine. 
 In addition, eight other compounds were isolated from the butanol fraction of 
the 30% ethanol extract of the plant. Among them were nucleosides 2’deoxy-
uridine (7), 2’deoxy-thymidine (8), uracil (4), and adenine (5) [52]. Three other 
small molecule structures, 3-indole-carboxyllic acid (6), anisic acid (10), and 
phenylacetamide (11) were also isolated and confirmed by comparison with NMR 
spectra from the literature [53-55].   
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Table 6. Spectral Assignments for Compound (3), 
Hydroxygalegine 
 
Position δ C (mult.) δ H (mult., J in Hz) COSY HMBC  
2 156.34   H-5 
5 45.5, 2H 4.09, d (7.1) H-10, H-6  
6 119.52, 1H 5.31, t (7.1) H-10, H-5 H-8, H-5. H-10 
7 140.28   H-8, H-5. H-10 
8 60.53, 2H 4.12, s  H-6, H-10 
10 20.97, 3H 1.81, s H-6, H-5 H-6, H-8 
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 Compounds (1) and (2) were screened in silico for their ability to bind to 
the crystal structures of AR wild type (PDB ID: 2YHD), and two mutant varieties 
relevant to the progression of prostate cancer with crystal structures available in 
the Protein Databank, T887A (PDB ID: 1I37) and H874Y (PDB ID: 2Q7K) [20, 
21]. Binding affinities resulting from docking experiments were compared with 
the AR's natural ligands, testosterone and dihydrotestosterone (DHT), known non-
AR binders beta-sitosterol and stigmaterol, known AR-binding small molecule 
natural products EGCG and atraric acid, and compounds implicated in BPH-
related prostate health: apigenin, emodin, baicalein, genistein, icaritin, 
xanthohumol (see Tables 7-9) [22]. Compound (1) and (2) were found to have 
binding affinities comparable to atraric acid (-6.1, -6.3, -6.8 kcal/mol in 2YHD, 
1I37 and 2Q7K respectively), and EGCG (-6.8, -4.2, -6.0 kcal/mol in 2YHD, 1I37 
and 2Q7K respectively) but did not bind as well as natural ligand testosterone (-
11.2, -11.2, -11.8 kcal/mol in 2YHD, 1I37 and 2Q7K respectively) or DHT (-10.9, 
-10.2, -11.3 8 kcal/mol in 2YHD, 1I37 and 2Q7K respectively). The top three 
modes of each compound docked are listed in Tables 7-9. 
 Because of promising in silico results, we sought to evaluate the ability of 
celosiadine A and B to inhibit the growth of prostate cancer cell lines in vitro. 
Testing of compounds (1) and (2) in in vitro prostate cancer cell assays supported 
in silico screening results by inhibiting the growth of AR-sensitive prostate cancer 
cells. Compound (1) and (2) were tested at 12.5, 25, and 50 µM concentrations. 
The butanol extract was tested at the 50 and 250 ppm concentration. Exposure 
time was for 6 hours and 24 hours. Statistically significant changes in the LNCaP, 
AR-sensitive cell line, were observed following 24 hours of exposure from the 
compounds as well as the crude extract from which they were derived. This effect 
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was not observed in the PC3, androgen-independent prostate cancer cell lines 
(Fig. 34, 35, 36).  
 These results suggests that celosiadine A and B may be the health relevant 
principles responsible for the use of Iresine celosia in promoting prostate health, 
and that their mechanism of action may be androgen-receptor specific. Further 
testing is warranted to determine the ability of these compounds to bind to the AR 
in vitro, and their ability to act in an anti-androgenic mechanism, as is seen with 
other plant-derived compounds like EGCG and atraric acid. These non-steroidal 
compounds work by preventing translocation of the AR to the nucleus, and thus 
preventing the transcriptionally active conformation of the AR from turning on 
genes relevant to the proliferation and differentiation of prostate cancer. Because 
antiandrogen therapies are often later converted by the body into androgen 
receptor antagonists, resistance to antihormone therapy can be a major problem 
for long-term treatment of prostate cancer. Should celosiadine A and B prove 
effective as antiandrogens, they could add to the current armament of therapies a 
structurally novel and natural aid to help promote prostate health. 
 
EXPERIMENTAL SECTION 
     General Experimental Procedures: Silica gel (230−400 mesh, Sorbent 
Technologies) and Sephadex LH-20 gel (Amersham Biosciences) were used for 
column chromatography, and pre-coated silica gel GF254 plates (Whatman Ltd., 
Maidstone, England) were used for TLC analysis. Semi-preparative HPLC 
separations were performed on a Hitachi Elite LaChrom system consisting of an 
L2130 pump, an L36 2200 auto-sampler, an L-2455 diode array detector and a 
Phenomenex Luna C18 column (250 ~ 10 mm, S-5 µm), all operated by EZChrom 
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Elite software. The UV spectra were measured on a Shimadzu UV-2550 
UV−visible spectrophotometer. All solvents were of ACS- or HPLC-grade and 
were obtained from Sigma-Aldrich (St. Louis, MO, USA) through Wilkem 
Scientific (Pawtucket, RI, USA). 1D and 2D NMR data were recorded on a Varian 
500 MHz instrument with dimethyl sulfoxide-d6 as solvent and TMS as internal 
standard. NOESY experiments were conducted using a three-pulse sequence with 
a mixing time of 400 milliseconds and 700 milliseconds. 1D NOE experiments 
were conducted with pulse width of 90 degrees, a relax delay of 1, 512 scans with 
a mix time of 500 mms and a block size of 16. HRESIMS data were acquired 
using an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). Optical 
rotations were measured on an Auto Pol III automatic polarimeter (Rudolph 
Research, Flanders, NJ, USA) at room temperature. The IR spectra were recorded 
on a Bruker Tensor 27 FT-IR and analyzed using OPUS Data Collection and 
Analysis software.  
     Plant Material: Three kilos of the aerial portions of the Iresine celosia plant 
were collected in Masaya, Nicaragua in September of 2008 and kindly provided to 
our laboratory by Iresine International, Inc. (Miami, FL, USA). The plant was 
authenticated by Edda Contreras (Iresine International, Inc., Miami, FL) and Mr. 
Peter Morgan, Master Gardener (University of Rhode Island College of Pharmacy, 
Kingston, RI), and a voucher specimen (16CK37-IRE21712H) has been deposited 
at the University of Rhode Island, College of Pharmacy, Medicinal Plant 
Greenhouse. 
     Extraction and Isolation: In order to reproduce the commercial formulation, 
comprised of 30% ethanol, in the laboratory, air-dried aerial portions (2.0 kg) of 
Iresine celosia were extracted by maceration with 30% ethanol (16 L, 3 times for 
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7 days per time period of 21 days) at room temp. 9 L of the aqueous solution was 
recovered and dried to 1.2 mL through rotary evaporation, and then extracted 
successively with n-Hexanes (1.2 L, 3 times), ethyl acetate (1.2 L, 3 times), and n-
butanol (1.2 L, 3 times) successively. The n-butanol fraction (8.93g) was purified 
through gravity column chromatography using silica gel (CHCl3-MeOH, 19:1 v/v 
to 1:1 v/v) to yield four major fractions (A-F). Fraction A was further purified 
using Sephadex LH-20 eluted with MeOH affording four fractions (20B-G). 
Fraction 20E was separated by semi-preparative HPLC, eluted with MeOH-H20 
with 0.1% TFA (10:90 v/v to 95:5 v/v in 25 min, 2 mL/min) to yield compounds 
7, 8, 9, and 11. Fraction 20F was similarly separated by semi-preparative HPLC, 
eluted with MeOH-H20 with 0.1% TFA (10:90 v/v to 100:0 v/v in 30 min, 2.5 
mL/min) to yield compounds 4 and 10. Fraction 20G was also separated by semi-
preparative HPLC, eluted with MeOH-H20 with 0.1% TFA (10:90 v/v to 95:5 v/v 
in 25 min, 2 mL/min) to yield compounds 5 and 6. Fraction E was further 
separated using Sephadex LH-20 eluted with MeOH to afford two main fractions 
(24A and 24B). Fraction 24B was separated by semi-preparative HPLC, eluted 
with MeOH-H20 (10:90 v/v to 100:0 v/v in 27 min, 3 mL/min) to yield 
compounds 1, 2, and 3. 
 Compound (1): light yellow amorphous solid; [α]D20 = +3.4o (MeOH); IR 
vmax 3380, 1700, 1600 cm–1; 1H and 13C NMR data, see Table 1; HRESIMS  m/z 
242.1500 [M+H]+ (calcd C11H19N3O3, for 242.1499). 
 Compound (2): a light yellow powder; [α]D20 = +10o (MeOH); IR vmax 
3380, 1700, 1600 cm–1; 1H and 13C NMR data, see Table 5; C11H19N3O2 as 
determined by HRESIMS at m/z 226.1547, [M+H]+  (calcd C11H19N3O2, for 
226.155). 
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 Compound (3): 1H and 13C NMR data, see Table 6 and were compared 
with previously reported values in the literature [27].  
 In silico Molecular Modeling Study: Crystal structures of the wild type 
human Androgen Receptors (PDB ID: 2YHD), the T877A mutant human AR 
(PDB ID: 1I37) and the H874Y mutant human AR (PDB ID: 2Q7L) were 
obtained from the Protein Data Bank (PDB) as a template for docking of 
compounds isolated from Iresine celosia [28]. Receptor macromolecules were 
checked for completeness and accuracy by overlapping with other known, 
reported androgen receptor crystal structures using Chimera [29]. Structures were 
cleaned and split from ligands with which they were crystalized, and residual 
water removed using the Accelrys Discovery Studio 3.5. Autodock Tools (version 
1.5.4) was used to add all hydrogens, including non-polar, Kollman charges, and 
solvation parameters [30]. After adding charges, all non-polar hydrogens were 
merged. Autogrid, a program included within Autodock Tools, was used to 
generate grid map size parameters, which were then incorporated into 
configuration files used for docking in Autodock Vina, with grid coordinates 
centered on the known ligand binding domain. Grid box dimensions were set to 
24.051 x 1.363 x 5.150, adjusting the spacing between the grid points to be 1Å.  
 ChemDraw3D was used to create protein databank (.pdb) files for all 
compounds used in docking experiments. Ligands were further prepared, with 
Gasteiger charges assigned, all non-polar hydrogens merged, and the number of 
torsions set using Autodock Tools. All bond rotations for ligands were 
automatically set in ADT using the Lamarckian generic algorithm (LGA). The 
exhaustiveness number was set to 16 and the solutions for each docked ligand 
were evaluated through analysis of the text files containing binding affinity data 
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(kcal/mol) and route mean square deviations (RMSDs), and inspection of .pdbqt 
files to assess physical configuration of docked molecules and reproducibility 
among docking modes. Batch files used to script automated docking procedures 
were prepared using the text editing program TextWrangler. Docking was 
conducted using Autodock Vina. 
 Known non-androgen receptor binders stigmasterol and beta-sitosterol 
were used as negative controls, while natural androgen receptor ligands 
testosterone and 5α-dihydrotestosterone (5α-DHT) were used as positive controls 
for docking studies [31]. In addition, a set of natural product structures associated 
with prostate health, including apigenin, emodin, baicalein, genistein, icaritin, 
xanthohumol, and known AR-binders atraric acid and EGCG were used as a set 
for comparison [22].  
 
 Prostate Cancer Assay: 
 The cellular cytotoxicity of the Iresine celosia extract and isolated 
compounds celosiadine A and B was evaluated using the Alamar blue assay 
(Invitrogen, Burlington, ON) as per manufacturer’s instructions. The Alamar blue 
assay measures cellular metabolic activity (and thus cellular viability) via the 
reduction of a nonfluorescent redox indicator to a fluorescent product by viable 
cells. The reduction of Alamar blue reagent by Iresine celosia extract-treated, 
compound (1)-treated, and compound (2)-treated cells were compared to that of 
vehicle control-treated cells. 
 Human LNCaP and PC3 prostate adenocarcinoma cells (ATCC, Manassas, 
VA) were cultured on 100 mm plastic tissue culture dishes (Falcon, Mississauga, 
ON) in alpha-MEM supplemented with 1% (v/v) antibiotic/antimycotic 
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(Invitrogen, Burlington, ON) and 10% (v/v) fetal clone III bovine serum 
(Hyclone/VWR Canlab, Mississauga, ON) and were grown at 37°C in 5% CO2. 
 Compounds (1) and (2) were tested at 12.5, 25, and 50 µM concentrations. 
The butanol extract was tested at the 50 and 250 ppm concentration. Exposure 
time was for 6 hours and 24 hours. 
 The cellular cytotoxicity of Iresine celosia extract was evaluated using the 
Alamar blue assay (Invitrogen, Burlington, ON) as per manufacturer’s 
instructions. The Alamar blue assay measures cellular metabolic activity (and thus 
cellular viability) via the reduction of a non-fluorescent redox indicator to a 
fluorescent product by viable cells. The reduction of Alamar blue reagent by the 
individual compounds and extract-treated and fraction-treated cells was compared 
to that of vehicle control-treated cells. 
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Abstract 
Iresine celosia is the sole active ingredient of the Odyliresin™ dietary supplement 
formulation currently marketed to humans worldwide as an antioxidant for the 
promotion of prostate health. Like many botanical dietary supplements, the 
ingredient lacks authentication methods to characterize its phytochemistry. This 
work presents an analytical method for high-performance liquid chromatography 
(HPLC) and development of an analytical finger print profile that can be used to 
standardize the Iresine celosia botanical extract. Of the eleven compounds 
isolated from this plant and identified on the fingerprint chromatogram, the 
appearance of two new cyclic guanidine alkaloid compounds unique to this 
botanical specimen are among the most abundant and serve as important marker 
compounds for the extract. In this study, a method for the quantitative analysis of 
the two new guanidine alkaloids (GAs) present in the Iresine celosia botanical 
extract formulation was developed, celosiadine A and B, or compounds (1) and 
(2) respectively. A lab-produced formulation of the aerial plant material was 
extracted with 30% ethanol and subject to sequential liquid-liquid partitioning 
with n-hexanes, ethyl acetate, and n-butanol. Samples of the manufacturer’s 
Odyliresin™ formulation were also subject to the same sequential partitioning. 
Butanol fractions, Lab-bu and Odyli-bu, were analyzed and the GAs quantified by 
HPLC.  Calibration curves were tested in triplicate and showed good linearity (r^2 
> 0.99) within the tested ranges and the concentrations of these compounds in the 
extracts were quantified based on the standard curves. The Lab-bu fraction 
appeared to have almost ten times as much of compounds (1) and (2) as the Odyli-
bu fraction, with compound (1) comprising 0.032% of the Lab-bu formulation, 
and 0.0032% of the Odyli-bu formulation, and compound (2) comprising 0.4% of 
the Lab-bu formulation, and 0.04% of the Odyli-bu formulation respectively. 
Identification of relevant marker compounds, analytical method development, and 
analytical finger print profiling can help to address the deficiency of knowledge 
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needed for botanical dietary supplement formulations like Odyliresin™ to achieve 
a level of quality production and safe use. 
 
Introduction 
 
 Analytical method development for botanicals used by humans in the form 
of dietary supplements has been identified as an important area of research by a 
variety of regulatory bodies, including the U.S. Congress, National Institutes of 
Health (NIH), Food and Drug Administration (FDA), National Institute of 
Standards and Technology (NIST), clinical researchers, including those seeking 
funding from the National Center for Complementary and Alternative Medicines 
(NCCAM), product manufacturers, and other industry stakeholders who seek to 
ensure that consumers have access to quality dietary supplement products [56-58]. 
Current good manufacturing practice (cGMP) regulations for dietary supplements 
require manufacturers to demonstrate that “specifications are met for the identity, 
purity, strength, and composition of the dietary supplements” [59]. However, 
regulations do not instruct manufacturers about particular analytical methods 
required to meet these stipulations. Rather, each botanical component requires a 
specific, scientifically valid authentication method in order to provide the 
necessary proof to comply with regulations.  
 In particular, analytical separation techniques like high performance liquid 
chromatography (HPLC) currently provide the most reliable and applicable 
authentication methods for botanicals. To accomplish this, however, it is 
necessary to isolate and identify selected “marker” compounds that make up an 
analytical fingerprint that is distinct for the selected species. Especially for less 
widely known botanicals, this work requires extensive phytochemical 
investigation of the plant, and usually includes the development of tailored 
isolation schemes, compound purification, and structure elucidation experiments, 
alongside the development of analytical methodology fitting to the botanical 
specimen to standardize extracts.  
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 Iresine celosia is a member of the Amaranthaceae family. The plant is 
native to Central America, Mexico and southern portions of the United States like 
Texas and Florida [60]. It has a history of use as a traditional medicine by the 
Mayan people of Chiapas Mexico, who used this plant for a variety of conditions, 
among them malaria, gonorrhea, and dropsy [35, 36, 38-40, 42, 43, 61]. To them, 
it was known as tlatlancuaya, although this name has been used to describe other 
botanical medicines in the region. In addition, the plant also has over 27 botanical 
synonyms [34-36, 38, 60]. Because of the many names ascribed to the plant, there 
is added utility to the development of chemical reference standards as this 
information can also be used in the taxonomical identification of the plant and 
products made therefrom. 
 Today, Iresine celosia is best known for its use as the sole active 
ingredient in the Odyliresin™ Antioxidant botanical formulation, used for the 
promotion of prostate health in humans [33]. The product is produced in a 30% 
ethanolic aqueous extract of the aerial portions of the plant. Although produced on 
small (1L or less) scale in single batches, cGMP regulations apply also to small 
scale manufacturers of dietary supplements like the makers of the Odyliresin™ 
Antioxidant botanical formulation. This work represents the first phytochemical 
investigation of this formulation resulting in the identification of marker 
compounds and their use in analytical profiling of the formulation. 
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Materials and Methods 
  
Plant Material 
 Aerial portions of the Iresine celosia plant were collected in Masaya, 
Nicaragua in September of 2008 and kindly provided to our laboratory by Iresine 
International, Inc. (Miami, FL, USA). The plant was authenticated by Edda 
Contreras (Iresine International, Inc., Miami, FL) and Mr. Peter Morgan, Master 
Gardener (University of Rhode Island College of Pharmacy, Kingston, RI), and a 
voucher specimen (16CK37-IRE21712H) has been deposited at the University of 
Rhode Island, College of Pharmacy, Medicinal Plant Greenhouse. In addition, 
three Odyliresin™ Antioxidant, 50 ml dispenser bottles were provided by the 
manufacturers from one batch of product, the only available at the time.   
 
HPLC Conditions 
 Semi-preparative HPLC separations were performed on a Hitachi Elite 
LaChrom system consisting of an L2130 pump, an L36 2200 auto-sampler, an L-
2455 diode array detector and a Phenomenex Luna C18 column (250 ~ 10 mm, S-
5 µm), all operated by EZChrom Elite software. The UV spectra were measured 
on a Shimadzu UV-2550 UV−visible spectrophotometer. All solvents were of 
ACS- or HPLC-grade and were obtained from Sigma-Aldrich (St. Louis, MO, 
USA) through Wilkem Scientific (Pawtucket, RI, USA). A linear gradient 
chromatographic technique was used at room temperature with the following 
solvent system: solvent A =  0.1% trifluoroacetic acid with filtered, deionized 
water; solvent B = methanol; starting at 10% A:90% B and rose via a gradient to 
40% A:60% B at 30 minutes. From 30 min to 35 min, solvent A 0%:100% B and 
continued to 40 minutes. From 40 to 42 minutes, 10% A:90% B and run to 52 
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minutes. The flow rate was 0.75 mL/min throughout. Detection was monitored via 
diode array detector between 200 nm - 520 nm wavelength. All HPLC-UV 
analyses were carried out with 15uL injection volumes. Compounds (1) and (2) 
were monitored at 212 nm. In addition, compound (3) was monitored at 210, (4) at 
256 nm, (8) at 264 nm, and (10) at 260 nm. The concentration of these compounds 
was quantified based on the standard curves. 
 
Preparation of extracts 
 
For analysis by HPLC 
 
 Lab-Neat formulation: Following manufacturer’s production instructions, 
a 30% ethanolic extract (16 liters) was added to cover and saturate 2 kilos of dried 
plant material, and set aside for three weeks with occasional (apx. every 72 hours) 
stirring. 9 liters of the ethanolic extract were recovered, dried to 1.2 L through in 
vacuo, and sequentially partitioned with n-hexanes, ethyl acetate and n-butanol.   
 Odlyi-Neat, Manufacturer’s formulation: 15 mL of the formulation neat, 
with ethanol removed and dried down to 10 mL, was subject to liquid-liquid 
partitioning sequentially with n-hexanes, ethyl acetate and n-butanol. The 
resultant n-butanol fraction was dried in vacuo and resulted in a 96.4 mg residue. 
Dried residues of these products were weighed and reconstituted to the 
appropriate concentration using HPLC-grade methanol. 
 Lab-bu and Odyli-bu test samples were generated by bringing up from dry 
weight in 30% HPLC-grade methanol and 70% DI-water a 250 mg/mL stock 
concentration, from which 150, 100, 75, 50, 25, and 10 mg/mL concentrations 
were derived. In addition, 500 mg/mL concentrations were made separately and 
also tested.  Samples were centrifuged prior to injection in HPLC, and all samples 
were injected with a 15 µL injection volume. Each sample was injected in 
triplicate and a linear calibration curves (r2 = 0.99) constructed by plotting the 
mean peak area percentage against concentration. The presence of compounds (1) 
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and (2) was determined with the use of 5-point calibration curves for standard 
compounds. Stock solutions were stored at 4°C (see Figure 37 -47). 
 
Identification of the isolated compounds 
For isolation and identification of standard compounds 
 Lab-Neat formulation was prepared as described above. The butanol-
soluble fraction (Lab-Butanol) was subjected to silica gel gravity column 
chromatography and eluted with chloroform and methanol (19:1 CHCl3:MeOH to 
1:1 CHCl3:MeOH), affording four major fractions. Fraction E resulting from 5:1 
CHCl3:MeOH elution was further purified using Sephadex LH-20 resin eluted 
with methanol. Fractions were evaluated using analytical HPLC. 
 Semi-preparative HPLC afforded the isolation of marker compounds (1) 
and (2). In addition, additional purification afforded compounds 3-11. Detailed 
analysis of the 1D and 2D NMR data allowed for the construction of the structure 
of Compound (1) and (2). Compounds 3-11 were identified based on 1H spectra 
and 13C and comparison with prior literature [62]. Details on this work are 
reported elsewhere (see Chapter 2). 
 
Standard Preparation 
 
 Stock solutions of the isolated GA standards, compound (1) and compound 
(2), were prepared as follows: 1-3 mg standard was accurately weighed. Next, a 
mixture of 30% HPLC-grade methanol and 70% filtered, deionized water was 
added and the solution was serial diluted to volume with the same solvent to 
afford samples of 1.00, 0.500, 0.250, 0.125, 0.0625, 0.03125, and 0.015625 
mg/mL concentrations respectively. Each sample was injected in triplicate and a 
linear five-point calibration curve (r2 = 0.99) was constructed by plotting the mean 
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peak area percentage against concentration. Each stock solution was stored at 4°C. 
In addition, compounds (3), (4), (8), and (10) were also tested though results were 
not reproduced in triplicate. Stock solutions of these compounds were prepared at 
concentrations relevant to each compound, as follows: (3) at 3.5, 1.75, 0.875, and 
0.4375 mg/mL; (4) at 1.9, 0.950, 0.475, 0.238, and 0.119 mg/mL; (8) at 0.4, 0.2, 
0.1, 0.05, 0.025 mg/mL; (10) at 0.55, 0.275, 0.138 mg/mL (see Figures 42-47). 
  
 
Detection Limit and Quantitation Limit 
 
 The limits of detection (LOD) and quantitation (LOQ) were determined 
based on the standard deviation of the response and the slope, which is one of the 
LOD and LOQ measurements in the ICH guidelines [63]. The LOD and LOQ 
were calculated as described as follows: 
 
LOD (µg mL−1) = 3.3 σ/S 
LOQ (µg mL−1) = 10 σ/S 
 
where σ = the standard deviation of the response, and  
          S = the slope of the calibration curve.  
 
To calculate σ, a calibration curve of the sample with compound that had a 
concentration similar to the LOD, LOQ was studied. The standard deviation of the 
y-intercepts of the regression lines was used as σ. For compound (1), LOD was 
calculated as 0.13 mg/mL, and LOQ as 0.39 mg/mL (see Table 11). For 
compound (2), LOD was calculated as 0.18 mg/mL and LOQ as 0.56 mg/mL. 
LOD and LOQ were not determined for compounds (3), (4), (8), and (10). 
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Results and Discussion 
 In the current study, a method was developed to analyze the content of the 
GAs, compound (1) and (2), novel botanical identifiers and potentially the health-
relevant principles of the Iresine celosia botanical formulation. Initially, four 
samples were analyzed: Lab-Neat, a lab-generated 30% ethanolic extract, Odyli-
Neat, the manufacturer's own 30% ethanolic extract, and butanol partitions of 
these fractions, Lab-Butanol and Odyli-Butanol. These samples were analyzed 
and the GAs quantified by HPLC-DAD. However, because 30% ethanolic crude 
extract's marker compounds were well below limits of detection in the form sold 
to patients, and saturated when the material was dried and brought up to detectable 
concentrations, further purification was required to standardize the extracts. 
Further purification steps are standard when dealing with complex mixtures, and 
in this case partitioning with hexane and ethyl acetate and finally butanol was 
required. With these defatting steps accomplished, the butanol fractions were 
analyzed for their presence of the two marker compounds. 
 The content of guanidine alkaloids within the complex botanical 
formulation of Iresine celosia is quite small. Compound (1) comprised 0.032% by 
weight of the Lab-bu formulation, and 0.0032% of the Odyli-bu formulation, and 
compound (2) comprised 0.4% of the Lab-bu formulation, and 0.04% of the 
Odyli-bu formulation. The Lab-bu fraction appeared to have almost ten times as 
much of compounds (1) and (2) as did the Odyli-bu fraction. Lab-bu fraction at 50 
mg/mL concentration contained amounts of compounds  (1) and (2) comparable to 
the Odyli-bu fraction at 500 mg/mL (see tables 12, 13, 18, 19). 
 Additionally, compounds (3), (4), (8), and (10) hydroxygalegine, uracil, 
2’deoxythymidine, and anisic acid respectively were also quantified in the Lab-bu 
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formulation, but were below the limits of detection for the Odyli-bu formulation 
(see Figures 50-53). Compound (3) comprised 0.002% by weight of the Lab-bu 
formulation, compound (4) comprised 0.004%, compound (8) comprised 
0.0008%, and compound (10) comprised 0.001% of the Lab-bu formulation. 
 The lack of relevant marker compounds is said to be the major limiting 
factor hindering the widespread adoption of quality control approaches for 
botanical supplements [30]. To allow for documentation that products meet 
manufacturer’s specifications and that products contain what their labels declare, 
analytical method development is needed. These methods define a level of quality 
that can be verified with each batch production. 
 Most notable among the compounds isolated from the Odyliresin™ 
botanical formulation are two novel cyclic guanidine alkaloids unique to Iresine 
celosia, the formulation’s sole component. The novelty of these molecules within 
the botanical specimen, and the abundance with which they are found in the 
formulation among other reasons allow for the use of these compounds as good 
markers to identify and authenticate both the Iresine celosia plant and the 
Odyliresin™ formulation. In addition, while guanidine alkaloids are found in a 
handful of plant species, only one other plant is known to possess 2-substittued 
imidazolines, making them structurally novel identifiers [64-70]. The 
Odyliresin™ botanical formulation also possess a number of nucleosides (among 
them, 2’deoxy-uridine, 2’deoxy-thymidine, uracil and adenine), along with some 
additional small molecule structures (3-indole-carboxyllic acid, anisic acid, and 
phenylacetamide). 
 Biologically active ingredients that represent the “health-relevant principle 
components” of the formulation are also preferred as marker compounds [30], 
although this point is elsewhere contested as unnecessary [56]. In silico screening 
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suggests that the GA marker compounds may also play a role in the biological 
activity of the extract when used for promotion of prostate health. Docking 
experiments revealed that the new compounds bind to the human androgen 
receptor, both wild type and mutant forms relevant in prostate-cancer progression. 
Further testing in LNCaP AR-sensitive cell lines showed favorable activity of the 
compounds in the 12.5-50 µM range, while leaving PC3, AR-independent cell 
lines otherwise unchanged (see Chapter 2). Like other botanical structures EGCG 
and atraric acid, these compounds may also act as anti-androgens. Thus, due to 
their novelty and potential health-relevant component for the species in question, 
and the relative abundance with which they are found in the plant, these 
compounds can be used as unique identifiers to the botanical specimen, and could 
potentially be used to quantify the potency of what is likely the health-relevant 
principle within the extract.  
 The isolation of single active principles from botanical natural product 
dietary supplements like the Odyliresin™ formulation of  Iresine celosia will 
allow for further evaluation of this formulation’s safety when used in humans and 
efficacy when used as a remedy to promote health of the prostate, and 
authentication of the formulation’s ingredients using the presence of chemical 
marker compounds in the commercial product. 
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Perspective on the Regulatory and Scientific Evaluation of 
Botanical Dietary Supplement Safety 
 
Abstract 
 The release of the Draft Guidance for Industry, Dietary Supplements: New 
Dietary Ingredient Notification and Related Issues in July 2011 marked a turning 
point for the dietary supplement industry. The document outlined 
recommendations for the new dietary ingredient (NDI) submission process, 
including a battery of pre-clinical tests required for submission prior to 
introduction of a product into interstate commerce, and with it defined a level of 
scientific testing heretofore unprecedented in the industry. As regulatory 
requirements to provide extensive toxicological testing data on botanical dietary 
supplements increase, without a corresponding increase in resources for 
companies called upon to provide such data or for regulators of the industry, in 
silico screening of natural product structures presents a resource-conscious 
strategy that could play a role in the risk assessment of botanical ingredients. 
Based on knowledge of structural features of compounds from botanical natural 
products known to be toxic, new compounds for which little or no toxicological 
data exists could be screened for similar functional groups and structural alerts 
generated. This information could then be used to guide chemical and 
toxicological testing resources to where they are needed most, as well as 
streamline the regulatory review of these products. In this work, a review of 
regulation of the dietary supplement industry since 1994 was conducted, with 
emphasis on the development of current thinking on the interpretation of the NDI 
notification system. A survey of use of in silico methodology for chemical risk 
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assessment is also discussed, as well as how such a method may be applied to 
botanical natural product structures in particular. 
 
The Regulatory Landscape 
 In the U.S. marketplace alone, consumers continue to spend increasing 
amounts on botanical dietary supplements, from $3 billion in 1996 to $5 billion in 
2010 [71].  More widespread use of herbal products has resulted in increased 
attention to the safety of these products by consumers in the market place, 
manufacturers, and regulatory bodies. The passage of the Dietary Supplement 
Health and Education Act (DSHEA) in October 1994 authorized the U.S. Food 
and Drug Administration (FDA) to extend its authority to monitor and evaluate 
the safety, quality and labeling of dietary supplements. Core elements of the 
amendment to the Food, Drug and Cosmetic Act resulting from the passage of 
DSHEA include enhanced reach of the FDA to monitor dietary safety and quality, 
require pre-market notification, conduct labeling oversight, and post-market 
surveillance. Of these, the ability to monitor safety and quality through the use of 
pre-market notification has caused the greatest difficulty in compliance for 
botanical dietary supplements manufacturers.   
 To specify, monitoring dietary supplement safety and quality includes the 
authority to impose an immediate ban of products that pose an imminent hazard, 
impose requirements for Good Manufacturing Principles (GMP), inspect facilities, 
and collect adverse event reports associated with dietary supplement use. 
Instituting pre-market notification requirements works to prohibit any new dietary 
ingredient (NDI) for which there is inadequate information from entrance into 
interstate commerce. For those ingredients that are considered new, manufacturers 
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must provide reasonable assurance that it does not present a significant or 
unreasonable risk of illness or injury. However, debate over what constitutes a 
new dietary ingredient and the information needed to provide such a reasonable 
assurance is a current point of discussion among manufacturers, trade groups, and 
regulators of dietary supplements. 
 The dietary supplement industry has been operating under the New Dietary 
Ingredient (NDI) submission process since the 1994 passage of DSHEA. When 
DSHEA was signed into law, the legislation modified the Federal Food, Drug and 
Cosmetic Act (FDCA) by adding section 413, which outlines requirements to 
market a new dietary ingredient or a dietary supplement that includes a new 
dietary ingredient [72, 73]. The term new dietary ingredient is defined as “a 
dietary ingredient that was not marketed in the United States before October 15, 
1994 and does not include any dietary ingredient which was marketed in the 
United States before October 15” [74]. Specifically, this statute requires the 
manufacturer or distributor of a NDI, or of the dietary supplement that contains 
the NDI, to submit a premarket notification to FDA at least 75 days before 
introducing the supplement into interstate commerce or delivering it for 
introduction into interstate commerce, unless the NDI and any other dietary 
ingredients in the dietary supplement “have been present in the food supply as an 
article used for food in a form in which the food has not been chemically altered” 
[75]. Providing proof for this claim, however, is quite specific. Sales records, 
manufacturing records, commercial invoices, magazine advertisements, mail order 
catalogues, and sales brochures are all acceptable forms of evidence; affidavits 
alone are not [76]. Supposing these forms of proof can be supplied, they apply 
only if the currently marketed dietary supplement formulation has been in no way 
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chemically altered from the product as it existed prior to 1994. In addition, 
because no official list of dietary ingredients that can be considered 
“grandfathered” is recognized by regulatory authorities, it is rarely the case that 
supplement manufacturers are able to prove that their product is not new, even if it 
has a history of use as a traditional botanical medicine. Thus, most botanical 
dietary supplements are subject to the NDI submission process. 
 For those dietary supplements that must complete the NDI submission 
process, a new level of scientific rigor and premarket testing is outlined in the 
Draft Guidance document, heretofore unprecedented in the industry. Although the 
NDI submission provision has existed since the 1994 passage of DSHEA, recent 
debate in the dietary supplement community has centered around whether or not 
recent enforcement efforts have added greater rigor to the provision than was 
originally intended in the law. This point of debate matters to manufacturers of 
dietary supplements because the level of scientific testing outlined in recent 
legislation and regulatory guidance documents rises to a level of rigor that may 
not be appropriate for dietary supplements, and so cost-prohibitive as to put many 
dietary supplement companies out of business.  
 It has been pointed out elsewhere that the provisions required for premarket 
testing of dietary supplements and the wording copies almost directly from 
provisions outlined for the testing of food additives [77]. This is a significant 
point of contention, since the passage of DSHEA can be viewed historically as a 
battle between regulators and supplement manufacturers about whether or not 
dietary supplements could be considered and thus recalled as illegal food additives 
(for which prior market testing must demonstrate the safety with scientific 
evidence) or their own distinct regulatory class, neither food, food additive nor 
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drug, but dietary supplements (which do not require premarket proof of safety, 
only a reasonable expectation of safety, which lays the burden of proof that a 
product is unsafe upon regulators in order to issue a recall) [78]. Ultimately, the 
view that dietary supplements were not food additives and did not require proof of 
safety, but only a reasonable expectation of safety, carried the day and DSHEA 
was written and passed to reflect this thinking. DSHEA specifically noted that 
dietary supplements are not to be treated as food additives. This was pointed out 
in the 1994 law because such testing is not necessarily appropriate for the 
supplements being tested. Thus, an NDI Draft Guidance that has copied pre-
market testing provisions from food additive premarket safety testing guidance 
documents would be out of line with DSHEA. 
 In addition, as the majority of the dietary supplement industry is comprised 
of small companies, employing 20 or fewer, such testing may be cost prohibitive 
[79]. Even if the industry were to comply by providing what amounts to millions 
of dollars in pre-market chemical characterization and toxicological testing for 
each new dietary ingredient brought to market, it is unclear that the regulatory 
authorities have the manpower to cull and make use of the information submitted. 
At the time of commentary on the NDI submission process in 1997, the agency 
estimated the number of NDI notifications that would be filed annually would be 
between zero and 12 [80]. However, the fact that there are “only” 700 submissions 
annually even though there are an estimated 55,600 dietary supplement products 
on the market is now a figure used as an indication that the industry has been lax 
with compliance [81].  
 This change in agency thinking indicates that a shift has occurred toward a 
more stringent NDI submission policy, requiring more scientific information prior 
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to product launch. Helping manufacturers clear the hurdle of regulatory 
compliance with an enhanced scientific framework may present a new area of 
opportunity for contract laboratories, including natural products laboratories 
housed in academia that specialize in analytical chemistry and pharmacology, and 
are willing to work as contract laboratories under an academic umbrella. 
Understanding the development of current thinking on the NDI provision may 
help to clarify potential avenues whereby information required for NDI 
submission, or what amounts to preclinical testing of botanicals, could be 
accomplished in a cost-effective, resource-conscious manner. 
  
A Reasonable Expectation of Safety 
 In September 1997, FDA issued a Final Rule on Premarket Notification for 
a New Dietary ingredient [82], to clarify the “procedure by which a manufacturer 
or distributor of dietary supplements or of a new dietary ingredient is to submit 
under the Food Drug and Cosmetic Act the information on which it has concluded 
that a dietary supplement containing an NDI will reasonably be expected to be 
safe” [83]. Although additional clarification is outlined in the rule, manufacturers 
and distributors of dietary supplements still required guidance on a number of 
issues related to new dietary ingredients and requirements for notification 
submissions. On January 4, 2011, the Food Safety Modernization Act (FSMA) 
was signed into law [84]. The legislation included in section 113 required that 180 
days after enactment of FSMA, the FDA issue a guidance document on NDIs. 
FSMA directed the guidance to include provisions that clarify when an ingredient 
is considered an NDI and when the manufacturer or distributor of a dietary 
ingredient is required to provide the required information under section 413 of the 
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FDCA [85]. FSMA also directed FDA to include the evidence needed to 
document the safety of NDIs as well as appropriate methods for establishing the 
identity of NDI. On June 21, 2011, one of the original sponsors of DSHEA, 
Senator Hatch (R-UT), alongside Senator Harkin (D-IA) submitted a letter to 
Congress calling for the release of the guidance document to “provide clarity, 
predictability, and certainty to dietary supplement manufacturers and the public on 
FDA’s interpretation and expectation related to the marketing of NDIs.” In July 
2011, the Draft Guidance for Industry: Dietary Supplements: New Dietary 
Ingredient Notifications and Related Issues was released for public comment [86]. 
If FDA is able to meet all of its program priorities, a final NDI guidance is 
anticipated for 2014 [87].  
 The draft guidance is presented in a question-and-answer format to help 
industry determine when a dietary ingredient is new, deciding when premarket 
safety notification is necessary, and what type of information is needed for a 
complete notification. While the statement that any dietary ingredient marketed in 
the US before October 15, 1994 is exempt from the need to file an NDI seems 
straight forward enough, the information required to prove that a dietary 
ingredient was marketed before that time is very specific. The dietary ingredient 
must have (1) been sold or offered for sale (2) as a dietary supplement, in bulk as 
a dietary ingredient for use in dietary supplements, or as an ingredient in a blend 
or formulation of dietary ingredients for use in dietary supplements (3) in the 
United States (4) before October 15, 1994, and (5) not have undergone any 
changes in manufacturing processes that would alter the chemical composition of 
the ingredient or (6) changed the composition of materials used to make the 
ingredient [88]. To establish that marketing took place in the U.S., the identity 
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(e.g., chemical or botanical name) and form (e.g. ground herb, water extract, oil) 
of the marketed ingredient, and whether the ingredient was marketed as a dietary 
ingredient or for some other purpose, must be included in the evidence used. Valid 
forms of evidence include written business reports, promotional materials, or press 
reports with a contemporaneous date prior to October 15, 1994. Sales records, 
manufacturing records, commercial invoices, magazine advertisements, mail order 
catalogues and sales brochures are all acceptable; affidavits alone are not. In short, 
the requirements to prove that a dietary ingredient is “grandfathered”, and does 
not require a NDI notification, is extensive and very difficult to achieve, thus 
requiring that most dietary supplements on the market today submit NDI. 
 Within the new dietary ingredient notification, filers are asked to include 
information that makes the case to the FDA that there exists for their products a 
standard of safety, defined as a “reasonable certainty of no harm.” The NDI 
Guidance states,  
The NDI safety standard is different than the standard for food 
additives, drugs, pesticides, and other FDA-regulated products. 
Recommendations in guidance documents that are tailored to the safety 
assessment needs of other FDA-regulated products may not always be 
appropriate for dietary ingredients and dietary supplement…You should 
use your own best judgment in compiling scientific evidence that 
provides a basis to conclude that the NDI that is the subject of your 
notification will reasonably be expected to be safe when used under the 
conditions recommended or suggested in the labeling of the dietary 
supplement in the notification….You must provide the information that 
forms the basis on which you have concluded that a dietary supplement 
containing the NDI will reasonably be expected to be safe under the 
supplement's labeled conditions of use (21 U.S.C. 350b(a)(2)). In 
general, this information should include an adequate history of safe use, 
safety studies, or both [88].  
   
This “reasonable expectation of safety” is phrased in the FDCA Sec 402(f)(1)(B) 
as a “reasonable assurance that such (an) ingredient does not present a significant 
or unreasonable risk of illness or injury.” 
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 In outlining what sorts of information may be used in the NDI submission in 
order to reach such a conclusion, the draft guidance introduces a scientific 
framework, involving animal and human safety studies that are required when 
history of use data and literature are inadequate [89]. These include an extensive 
battery of toxicological testing used in the submission of new drug applications. 
 For a botanical supplement like Iresine celosia, the NDI is intended for daily 
chronic use, and has a documented history of safe intermittent use, and the 
proposed use of the NDI leads to intake levels that are the same as or less than the 
levels consumed historically, the following types of data are recommended [90]: 
(1) A three-study genetic toxicity (gentox) battery (bacterial 
mutagenesis, in vitro cytogenetics, and in vivo mammalian test) 
that includes a test for gene mutations in bacteria, either an in 
vitro mouse lymphoma thymidine kinase+/- gene mutation 
assay (preferred) or another suitable in vitro test with 
cytogenetic evaluation of chromosomal damage using 
mammalian cells, and an in vivo test for chromosomal damage 
using mammalian hematopoietic cells; 
(2) a 14-day range-finding oral study to establish a maximum 
tolerated dose (MTD) in an appropriate animal model; 
(3) a 90-day sub-chronic oral study in the same species as the 
range-finding study to establish an MTD and a No Observed 
Adverse Effect Level (NOAEL) for use in calculating the 
margin of safety; 
(4) a multi-generation rodent reproductive study (minimum 
two generations); and 
(5) a teratology study (rodent or non-rodent); 
except that the latter two studies are not needed if the product 
is labeled as not for use by women of childbearing age, 
pregnant or lactating women, and children 13 and younger. 
 
 The cost of this battery of tests was calculated at a presentation by 
international analytical testing lab firm Eurofins Scientific Incorporated in 
collaboration with Spheris Incorporated on December 12, 2011 at the Food and 
Drug Law Institute in Washington D.C. The findings are summarized in Tables 
20-21. For a botanical dietary supplement like Iresine celosia with only one new 
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dietary ingredient, supposing they are able to prove their historical use, estimates 
range anywhere between $573,310 - $690,600 for intermittent use, and 
$2,198,310 - $2,815,600 for chronic use. If they are unable to prove their 
historical use, testing costs can range anywhere between $2,758,310 - $3,382,500. 
These numbers represent starting points, of course, as additional testing may be 
needed (see Table 20-21). The Draft Guidance also goes on to mention that, 
“based on the nature of the NDI and the results of other testing special studies 
(e.g., carcinogenicity, ADME) may be needed to provide a reasonable expectation 
of safety. Other non-clinical studies to assess immunotixicity and neurotoxicity 
should be conducted on a case-by-case basis, as appropriate.” 
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Table 20:  
 
 
 
Table 21: 
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 Currently, funding to conduct studies to evaluate the safety and efficacy of 
dietary supplements is extremely limited. “It is impractical to think that any 
government agency, institute, or private organization could provide sufficient 
funds to adequately test the safety of tens of thousands of dietary supplement 
products often marketed in combinations that may change in formulation from 
year to year” [91]. The burden to conduct such testing has fallen to dietary 
supplement companies. Those who cannot afford the extensive toxicological 
testing outlined in the NDI may be forced out of business. In addition, regulators 
do not have the manpower needed to sift through these documents and 
toxicological testing results, even should companies be able to afford them. 
 Nevertheless, in spite of historical use and a generally accepted perception 
that “natural” equates to safe, it is true that some natural product preparations 
possess compounds that are known to be harmful when ingested by humans at 
higher dosages, when taken over longer periods of time than is appropriate 
(exposure), when taken in combination with prescription drugs (herb-drug 
interactions), or used by certain high-risk patient populations (i.e., those with 
compromised kidney and liver function) [92, 93]. Thus, the challenge remains, to 
evaluate the safety of botanicals and preparations prior to introduction to interstate 
commerce, to remain conscious of resources available to manufacturers and 
regulators of dietary supplements, to test botanicals within a framework true to the 
intent of DSHEA, and to use best judgment to support a reasonable expectation of 
safety. 
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Understanding the Risk Profiles Presented by Herbal Medicines: 
A Question for Pharmacognosy 
 While it is true that “natural” does not equate to safe, it is also true that the 
toxicity profiles of herbal medicines differ from those presented by toxic 
chemicals, food additives and synthetic pharmaceutical compounds. For this 
reason, they are and should continue to be regulated accordingly. When data was 
evaluated from 55 countries between 1968-1997 was evaluated, analysis published 
in the British Medical Journal noted that adverse events from herbal remedies 
“amount to only a tiny fraction of adverse events associated with conventional 
drugs held in the same (WHO) database” [11, 94]. Most of our risk profiling and 
test parameters concerning compounds we ingest grow out of the pharmaceutical 
paradigm that tests single molecular entities with potent and specific biological 
effects. However, herbals present a very different risk profile, both due to their 
dosing and due to specific presence or absence of structural features and 
functional groups. One major reason the safety profiles of dietary supplements and 
pharmaceuticals differ is because their chemistry differs. 
 The current risk assessment methodologies for chemicals regarding human 
toxicity endpoints are often derived from those for preclinical studies of 
pharmaceuticals. The methods for hazard assessment are largely the same for 
industrial chemicals, pesticides, and drug candidates. But this approach may not 
necessarily be appropriate for the risk assessment of herbal medicines now 
available as dietary supplements. Understanding and using the information we 
know about the action of phytochemicals present in herbal medicines, and the 
chemistry associated with their toxicity, is being under-utilized in the production 
of herbal dietary supplements, and their safety review by regulators. 
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 For dietary supplement safety concerns unrelated to adulteration, 
contamination, or other manufacturing and quality control procedures, but rather 
those that are inherent to the botanical preparations themselves, it is important to 
understand the toxic liabilities associated with phytochemicals present in botanical 
preparations in particular. It is to be acknowledged that herbal medicines, in use, 
are usually complex mixtures whose dynamic pharmacology is the result of a 
biochemical matrix of molecules that act to carry secondary metabolites 
throughout the body. The biological action of complex botanical mixtures is 
thought to be the result of isolable single molecule principles. Their bioactivity, 
including toxicity, is the result of chemical structures and chemical properties. 
The scientific discipline and collected wisdom encompassing the study of the 
chemistry, pharmacology, and toxicology of these secondary metabolites and their 
use in complex preparations is known as pharmacognosy. The findings of the 
science of pharmacognosy can and should b e applied to the evaluation of the 
safety of botanical dietary supplements. 
 In many cases, the active forms of secondary metabolites that are the basis 
of any rational phytotherapy are often prodrugs whose active form is generated 
through metabolic bioactivation in vivo, usually through Phase I metabolism. 
Thus, the active forms of molecules giving rise to favorable bioactivity, as well as 
toxic bioreactivity, is often the results of fleeting metabolites that fall into two 
broad categories: free radicals, and reactive electrophiles that are highly water 
soluble, and made more so by the oxidation, reduction, and hydrolysis resulting 
from Phase I biotransforming enzymes, cytochromes p450 (CYP enzymes). Due 
to the presence of reactive metabolites, the functional macromolecular structure of 
endogenous targets, like proteins and nucleic acids, can be altered in vivo. Their 
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effects range from chemoprevention in some cases, generally for weaker 
electrophiles with longer half lives, and mutagenesis and cell death in others, 
particularly for those that form briefly and whose targets are indiscriminate [11]. 
The resultant reactive intermediates can bind covalently to DNA and proteins, 
leading to organ toxicity and even carcinogenicity. In addition, some 
phytochemicals are shown to form reactive intermediates capable of irreversibly 
inhibiting various CYPs, which are critical to the metabolism and elimination of 
xenobiotics from the body, including therapeutic drugs. Less frequently, herbal 
compounds can also be converted to toxic or carcinogenic metabolites through 
Phase II metabolism enzymes that carry out reactions like glucoronidation 
sulfonation, acetylation, methylation, and glutathione conjugation. 
 The fleeting, reactive nature of these compounds pose considerable 
analytical challenges in attempts to determine their properties. It is understood that 
herbal medicines, often comprised of multiple active substances, undergo 
complicated fates in vivo. These fates can often be difficult to study, to follow and 
trace throughout the body, as intermediates responsible for biological reactivity 
are often fleeting in nature, and can be metabolized rapidly. For this reason, 
attempts to understand the absorption, distribution, and metabolism (ADME) and 
toxicity may best be accomplished by leveraging analysis of the structures isolated 
from phytochemicals, and evaluating their ability to form BRIs in vivo. 
 Screening natural product structures isolated from herbals used in dietary 
supplements for their likelihood to form such metabolites is an important step in 
identifying potential liabilities [15]. This screening can be conducted via a 
structure-based approach, in comparison with structures from herbal medicines 
that are known to be toxic, or converted in vivo to electrophilic mutagens and 
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carcinogens, and renal- or hepato-toxins. The study of reactive metabolites was 
pioneered in the 1940s through the work of James and Elizabeth Miller, who 
studied the mechanisms of action and metabolism of the carcinogenic azo dye 4-
dimethylaminoazobenzene (DAB), formerly used as a food coloring [95]. Further 
study of the mechanisms of action and metabolic fate of a large number of 
carcinogens led to the identification of several chemical functional groups and 
substructures (Structural Alerts, SA) that are used to screen for toxic liabilities for 
pharmaceuticals, environmental toxins, and food additives to this day [16, 96]. 
Many functional groups in chemical structures are known to be associated with 
the formation of reactive metabolites, very often catalyzed by the CYP enzymes. 
It is important to keep in mind, however, not all compounds with such functional 
groups are toxic, since formation of reactive intermediates is limited by the ability 
of CYPs to activate them. 
 Through the consideration of the types of biologically active compounds 
that may be present in the plant, it is possible to make educated estimates of the 
potential hazard of any given botanical, and prioritize their level of concern to 
safety. In their 2005 publication, Dietary Supplements: A Framework for 
Evaluating Safety, the National Academies of Science encouraged the use of 
chemical relatedness, or similarities to known toxic chemical compounds when 
considering the safety of botanical dietary supplements and their chemical 
components [97]. In the absence of information about the activity of the ingredient 
in question in humans, animals, or in vitro experiments, it is scientifically 
acceptable and appropriate to use information about safety concerns of related 
substances to inform a decision about the associated risk of the dietary supplement 
ingredients and their constitutive phytochemistry. 
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 While most botanical dietary supplements can be considered safe, we know 
the formation of reactive metabolites from compounds like saffrole (Sassafras oil), 
aristolochic acid (Aristolochiaceae family, especially genus Aristolochia and 
Assarum), methysticin (Kava Kava, Piper methysticum), and others have been 
reported [92]. Their toxicity arises primarily from the presence of six biological 
reactive intermediates, ranging in electrophilicity, from highly reactive and 
positively charged, to more stable, neutral electrophiles: carbocations, nitrenium 
ions, epoxides, quinones, quinone methides, and simple Michael acceptors (MAs). 
Other structural alert groups exist within natural products, including acetylenes, 
benzodioxoles, and terminal alkenes, among others (see Fig. 56). Of the 57 known 
structural alerts associated with mutagenicity and genotoxic carcinogenicity, 16 
regularly occur within botanical natural products [11, 98].  
 Awareness of the presence of these compounds can be used in early product 
development, just as it is in early drug discovery, to evaluate the possibility of a 
given compounds becoming a metabolic liability. The need to assess the ability of 
a chemical to act as a mutagen or genotoxic carcinogen is one of the primary 
requirements in regulatory toxicology, as is assessing the ability for a compound 
to induce liver injury by inhibition of CYP enzymes [17, 21, 22, 24, 25]. 
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Fig. 59: Common Chemical Structural Alert Groups from 
Natural Products 
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Leveraging Accumulated Knowledge and Existent Strategies 
 Structural alerts (SAs) for toxicities like mutagenicity and carcinogenicity, 
and CYP-related metabolism have been identified and codified into software 
programs by using existing knowledge, expert human judgment, bioassay data, 
and other modeling approaches [99]. These computer programs can assist in 
predicting the potential propensity for a chemical, or libraries of chemicals, to 
cause particular effects. A wide range of approaches and algorithms are 
incorporated into metabolism prediction software, with some using the structural 
features and physiochemical properties of test substrate compounds to predict the 
most likely metabolic sites. Some also incorporate docking studies and molecular 
dynamics simulation studies to assess P450-related pharmacological processes 
[100]. Apart from predicting only the possibility of particular sites of metabolism 
resulting from the biotransformation of a molecule, some software programs are 
designed to calculate the probability of a compound to be metabolized at a 
particular site, as well as other physiochemical parameters. Several proprietary, 
but few public, in silico methods are available for assessing ADMET properties. 
 Whatever method or algorithm is used, in silico toxicology, or the 
computational assessment of toxic liabilities, can allow researchers to evaluate a 
large number of chemicals, with consideration for a variety of endpoints, and 
ranges of exposure conditions considered simultaneously.  Other benefits include 
a substantial reduction, replacement, and refinement in the need for biological and 
particularly animal toxicological testing in establishing the safety of chemical 
substances. In addition, because bioactive and bioreactive intermediates formed 
from phytochemicals are often fleeting intermediates produced in vivo, in silico 
work has the added advantage of exploring these compounds in simulated studies. 
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The strategy can be cost and time effective, and provides information that can 
guide appropriate further testing and the conscientious use of resources. 
  These programs are used by regulators throughout the FDA, the EPA, by 
industry and academic researchers alike to evaluate a wide variety of chemical 
substances [101-103]. For instance, regulators at the US Food and Drug 
Administration’s Office of Food Additive Safety (OFAS), who administer the 
program that evaluates the safety information and industry submissions for 
various categories of food substances, including food additives, employ structure 
activity relationships (SAR) studies to evaluate the risk posed by new chemicals in 
these submissions [16]. It has been pointed out elsewhere that the framework 
wording and most of the scientific standards presented in the NDI draft guidance 
for dietary supplements are borrowed heavily from the food additive review 
process, so much so that the two “seem to be indistinguishable” [77, 104]. While 
the testing frame work and scientific standards required for NDIs may be new to 
the dietary supplement industry, regulators and manufacturers have already 
encountered the challenges presented by these provisions to some extent within 
the framework of food additive regulation, and developed working solutions to 
these challenges. Computational screening for structural alerts generates threshold 
of concern that then guides appropriate toxicological testing. A similar strategy 
can and should be applied to the evaluation of dietary supplements, especially 
considering that dietary supplements are to be regulated less stringently than food 
additives, under DSHEA. 
  It is important to keep in mind that models are guides, not hard forecasts. 
While a great deal of computational work, with a vast amount of expert 
knowledge that allows for a broad scope evaluation of toxic liabilities associated 
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with structures, it must be kept in mind that all models, even animal and cell 
culture models, are approximations. In silico predictions are most often conducted 
alongside other testing strategies, and these data constitute an integrated testing 
strategy. Assessing the relative value of information derived from computational 
toxicology can and should be weighed alongside other, different pieces of 
available information that has been gathered when making an overall risk 
assessment, and when considering what other information may be needed to 
conduct a robust assessment. 
 
Conclusion 
 The consumption of any botanical ingredient carries with it a certain degree 
of inherent risk to at least some segments of the human population, even for those 
plants used as foods or with a history of use for medicinal purposes.  
In the absence of comprehensive human clinical trials that establish safety, 
scientific evidence for risk can be obtained by considering whether the plant 
constituents are compounds with established toxicity or closely related in structure 
to compounds with established toxicity [32]. 
 Electrophilic structural alert groups commonly associated with natural 
product toxicity can be used to flag and identify potential natural product 
liabilities. Because neither regulatory bodies nor dietary supplement 
manufacturers have resources or time to conduct extensive toxicological testing, 
we can use structural features of natural product compounds to help us focus on 
areas of potential concern and prioritize efforts and resources. Computational 
capacity can be leveraged to flag and compile this data, and alert us to potential 
concerns. The basis of this work, however, is the isolation of chemical compounds 
present in laboratories of pharmacognosy. Their work plays a vital role in the 
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evaluation of potential toxicities associated with botanicals developed into dietary 
supplements by providing chemical structures needed for this type of risk 
assessment. Moreover, this data is required for new dietary ingredient (NDI) 
submission, and should be fully utilized when considering a justification for a 
reasonable expectation of safety. This helps both manufacturers and regulators 
leverage existing data necessary for NDI submissions to appropriately evaluate 
generalized potential risk profiles of botanical extract’s constitutive chemistry, 
and prioritize needs for future toxicological testing. 
 DSHEA set out dietary supplements as a different level of premarket safety 
concern from pharmaceuticals or food additives, because the chemical levels of 
concern are different. Understanding and using the information we know about the 
action of phytochemicals present in herbal medicines, and the chemistry 
associated with their toxicity, is being under-utilized in the production of herbal 
dietary supplements, and their safety review by regulators.  Neither manufacturers 
nor regulators have the resources available to do extensive pre-clinical testing of 
individual new dietary ingredients, which include extensive animal testing, and to 
review all the data that would be generated therefrom. The scientific 
understanding of the phytochemistry and resultant pharmacology of natural 
products should be better integrated in to the preliminary pre-market screening 
required by the NDI submission process, as it has been by other sectors of food 
and drugs, for which pre-market safety standards are more stringent. This 
information can and should be used to direct and guide the appropriate biological 
safety testing needed for herbal dietary supplements. Regulators and producers of 
pharmaceuticals, pesticides, and food additives have previously used structural 
alerts to help classify the safety or potential liability associated with compounds. 
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Such a strategy can and should be applied to dietary supplements, to assess the 
safety of their products, and to help prioritize their testing efforts.  
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Introduction  
 The aim of this work was to evaluate the safety of isolated phytochemicals 
from the Iresine celosia Odyliresin™ formulation using in silico drug metabolism 
and toxicology simulation studies, to predict possible metabolites generated in 
vivo, and their possible toxicological endpoints using ADMET predictor 
proprietary software. Compounds isolated from Iresine celosia botanical extract 
were screened using Simulations Plus ADMET Predictor proprietary software, to 
develop recommended maximum-recommended therapeutic oral dose and 
estimate overall toxic risk profiles of the compounds, including mutagenesis, 
chromosomal aberrations, reproductive toxicity, and human liver adverse effects. 
Previously, the extracts have been standardized, and the presence of guanidine 
alkaloids that may represent the health-relevant principle of the extract, as 
quantified. This work outlines the findings of screening these compounds for 
ADME/Tox using proprietary systems pharmacology software. In addition, to 
evaluate the formulation’s risk for potential herb-drug interactions, the ability of 
these compounds to inhibit CYP450 enzymes was also evaluated. Because many 
phytochemicals act as prodrugs, the generation of potentially bioactive or 
bioreactive (toxic) metabolites through Phase I biotransformation was also 
evaluated, and compared with botanical secondary metabolites known to cause 
toxicity. In silico screening of individual compounds isolated from the 
formulation suggest very little CYP inhibition a low level of safety concern 
overall for the compounds evaluated. Overall, these data support a reasonable 
expectation of safety when using this preparation as directed.    
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Methods 
 Phytochemicals isolated from Iresine celosia and their CYP450-produced 
biological metabolites were screened for their potential toxicity using the ADMET 
predictor proprietary software, a modeling tool from Simulations Plus. The 
ADMET Predictor Metabolism Module was used to determine whether 
compounds screened would be substrates for the nine most common CYP 
isoforms included in the model (2A6, 2B6, 2C8, 2E1, 1A2, 2C9, 2C19, 2D6 and 
3A4), whether an atom within a molecule could be a metabolic site, and what the 
predicted metabolite species could be. Metabolic site prediction models were 
trained on an extensively curated and updated version of the Accelrys Metabolite 
database along with published datasets of sites of metabolism and general review 
articles. The data is curated and updated to reflect more recent publications, and 
false positives removed when further literature investigations revealed a particular 
reaction in question to be mediated by a different CYP or through a non-CYP-
enzyme. Published literature has also gone on to validate sites of metabolism 
predicted by the model which were then experimentally verified, which suggests 
an added degree of confidence in the metabolism prediction models.  
 The ADMET Predictor Toxicity Module is used to predict toxicity relative 
to food products, pharmaceuticals, and environmental chemicals such as 
pesticides. The toxicity module offers information on a variety of end points, 
including estrogen and androgen receptor toxicity, chromosomal aberrations, a 
qualitative filter of mutagenicity in five strains of Salmonella bacteria with and 
without microsomal activation, human liver adverse effects, reproductive and 
developmental toxicity, maximum recommended therapeutic dose (MRTD), 
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carcinogenicity in rats and mice as TD50, and acute lethal toxicity in rats as 
LD50, among others.  
 Parent structures were input into ADMET Predictor using MedChem 
Designer. Analysis was run on these compounds with default settings, including 
running on pH 7.4 and pH 2. Output data containing toxicity, metabolism, and 
other physiochemical test results was exported to Excel for further analysis. Parent 
structures were then put into MedChem Designer, to generate metabolite 
structures and ADMET Predictor properties of metabolites taken. This data was 
also exported to Excel for further analysis. 
 Both models have been used extensively by a variety of companies within 
the pharmaceutical and chemical industries, as well as with the U.S. Food and 
Drug Administration with whom the company has recently developed 
collaborative agreement to further develop in vitro-in vivo correlation models to 
streamline regulatory review. These models are also licensed for academic use at 
steeply discounted rates, making them cost-effective for academic laboratories. 
These models have been extensively curated, are updated regularly, and do 
include some natural products in their data set. However, because natural products 
are very difficult to track as they are metabolized throughout the body, the natural 
product specific dataset that could inform metabolic site predictions and ADME 
toxicity modules like the ones used are quite limited. Thus, one draw back to the 
model that may exist is its training on pharmaceutical and environmental pesticide 
compounds, for which there is a greater wealth of metabolic and toxicity data. In 
addition, the model is unable to predict the formation of metabolites with short 
half-lives, such as the formation of epoxides. While it can make predictions about 
a compound’s ability to be metabolized by UGT-enzymes, it is primarily focused 
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on the prediction of metabolites formed through the nine CYP-isoforms listed 
above. Should a compound be metabolized by one of these enzymes, then undergo 
a Phase I reaction like sulfonation prior to being further metabolized by one of the 
CYP-enzymes included in the model, the model will be unable to make this 
logical leap. Thus, study and awareness of examples of known natural product 
metabolism were studied and also applied when evaluating results from both the 
Metabolism and Toxicity modules. 
 Internal cross-validation of the model was conducted using a set of botanical 
natural product structures known to inhibit CYP450 enzyme function, or to form 
biologically reactive intermediates, derived primarily from the Botanical Safety 
Handbook and other resources [12-14, 92]. 
 
Results 
 Enzymes primarily responsible for the metabolism of these GA compounds 
are CYP219, 2C19, and 2E1. Compound 1 and Compound 3 can be expected to be 
a substrate to CYP2C19 and 2E1. Compound 2 can be expected to be a substrate 
to CYP2C19 but not to 2E1. Compound 1 is also likely to be metabolized by 
CYP2D6. Compound 1 and 3 may be further metabolized through glucoronidation 
via the UGT2B7 enzyme. 
 Compound 1 and 3 may be contraindicated with use alongside protein pump 
inhibitors, as 2C19 is responsible for clearing this class of drugs. Because of 
further glucoronidation via UGT2B7, these compounds may be contraindicated 
with use in alcoholics and cancer patients. However, compounds 1 and 3 show 
very low likelihood of acting as mutagens. They may cause adverse liver events, 
but their maximum recommended therapeutic dose is high (above 3.16 mg/kg/day 
for a 60 kg-body weight/day), indicating less potential for overall toxicity. 
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 For Compound 2, the maximum recommended therapeutic dose is lower 
(below 3.16 mg/kg/day for a 60 kg-body weight/day). On further inspection, 
however, when LD50 and TD50 values for rats and mice are examined, it is found 
that the compound in its current formulation is present in concentration well 
below the concentrations required to cause lethality and toxicity in 50% of the 
respective populations.  
 Overall, these compounds each present an overall ADMET risk of 3/24, 
indicating that they are relatively low in risk as compared with the World Drug 
Index training set. 
 Outlines of findings for the guanidine alkaloid compounds are discussed 
below.  
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Overall Simulation Summary for Compound 1: 
 Compound 1 can be expected to be a substrate to CYPC19 and 2E1. 
CYP2C19 is important in the clearance of several classes of exceptionally widely 
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin 
and S-mephenytoin, as well as barbiturates, benzodiazepines, SSRIs, and the 
antimalarial proguanil. Possible contraindication with use alongside PPI (protein 
pump inhibitors). This compound may be a CYP2E1 substrate (60% likelihood). 
Very few drugs are cleared by 2E1, although it generates reactive oxygen species 
without substrate present, and are thus implicated in liver malfunction in 
alcoholics and cancer patients because of these reactive oxygen species. It is also 
likely that this compound is further metabolized through glucoronidation via the 
UGT2B7 enzyme. This enzyme is responsible for conjugation of bile acids, 
catechol estrogens, morphine and naproxen, hydroxymidazolam, gemfibrozil, 
AZT and many other drugs. Midazolam is also a substrate, and structurally similar 
to this compound, with both sharing an imidazo- ring. Possible contraindication 
with use in alcoholics, and cancer patients may be advised. Compound 1 does not 
appear to pose a liability to overall CYP-function (CYP_RISK: 0).  
 Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg 
dosage/60kg-body weight/day, is above 3.16 mg/kg/day, indicating less potential 
for overall toxicity. LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that 
would be lethal to 50% of rats was 768.94 mg/kg/day, requiring a 46.14 gram oral 
dose for a 60kg-body weight/day. TD50 or oral dose required to induce tumors in 
50% of rats after exposure over a standard lifetime (TOX_BRM_Rat), measured 
in mg/kg/day oral dose, is 1.95 mg/kg/day. This would require a human equivalent 
oral dose of 117 mg/day of the pure compound. In mice (TOX_BRM_Mouse), the 
number is 75.25 mg/kg/day, equating to a 4.52 gram oral dose each day of the 
single compound. TOX_Code Xr indicates that this compound may present a risk 
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in terms of carcinogenicity in chronic rat studies, because TOX_BRM_Rat is 
below 4 mg/kg/day oral dose. For a 60 kg body weight, that would amount to 240 
mg/kg/day of the pure compound. With MRTD above 3.6 mg/kg/day, a LD50 
calling for 46 gram/day oral dose, and a TD50 oral dose of pure compound at 117 
mg/kg/day, the compound in its current formulation is so dilute as to be presumed 
to be safe because it is present in an average daily dose in concentrations well 
below the concentrations above.   
 With an overall mutagenicity score representing the results of virtual Ames 
testing (TOX_MUT_Risk) of 1, on a score of 0-6 (with or without microsomal 
activation), this compound is not likely to present a serious mutagenic risk. Out of 
the ten virtual Ames tests conducted, this compound flagged one: an elevated risk 
for a metabolite of the pure compound likely to cause mutagenesis in TA1535 
strain of Salmonella typhimurium (TOX_MUT_m1535). Other qualitative risk 
estimations for toxic liabilities may also include elevated risk for reproductive 
toxin (TOX_REPR) at 72%, elevated risk for chromosomal aberration 
(TOX_CABR) at 79%.  
 Human liver adverse effect as the likelihood of causing elevation in the 
levels of a variety of liver enzymes, including elevated alkaline phosphatase 
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%, 
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 99%, and 
elevated SGPT enzyme at 74%. Thus, extremely concentrated doses of this 
compound may cause cardiac toxicity, chromosomal aberration, and reproductive 
toxicity. Elevation at higher doses may result in increased levels of alkaline 
phosphatase (98%), GGT (86%), LDH, SGOT (99%), and SGPT (74%) liver 
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination 
of liver enzymes levels would rise as a result of this compound, and that this 
compound could result in hepatotoxicity. Further indication of liver damage or 
disease, by the presence of higher levels of enzyme, the binary yes/no value, 
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TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase 
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the 
presence of compound 1. Thus, this compound may cause increased levels of 
enzymes involved with hepatotoxicity. 
 The model does not indicate that the compound would be toxic to the 
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and 
TOX_AR_Filter). 
 With an overall ADMET_RISK composite score for all of these models, on 
a scale of 0-24, this compound scored 3. 
 
BRIs present in Compound 1: 
Through CYP2E6, the oxidation of the secondary alcohol to a ketone, a Simple 
Michael acceptor product is formed (metabolite 4, M4).  This intermediate may be 
a possible mutagen (TOX_Code Mut), TOX_MUT_Risk 2 (out of 0-6).  
 
ADMET results: 
CYP2C19 Substrate: Yes 
 CLint: 0.034 
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism 
expressed in uL/min/mg microsomal protein. 
CYP2E1 Substrate: Yes (60%) 
MET_UGT2B7: Yes, 97%.  
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 2B7 
enzyme. Responsible for conjugation of bile acids, catechol estrogens, morphine 
and naproxen, hydroxymidazolam, gemfibrozil, AZT and many other drugs. 
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Midrazolam is also a substrate, and structurally similar to this compound, with 
both sharing an imidazo- ring. 
Results: Further metabolism of this molecule via glucoronidation via the UGT2B7 
enzyme is predicted. 
CYP_RISK: 0 
ADMET Code for metabolic liability - a computational filter developed by using a 
refined subset of the WDI. 
TOX_MRTD: Above 3.16 (65%) 
A qualitative assessment of the maximum recommended therapeutic dose 
administered as an oral dose in mg/kg/day. 
TOX_MUT_Risk: 1 
Represents the results of virtual Ames testing. Predicts overall mutagenicity by 
counting the number of “Positive” mutagenicity predictions. On a score of 0-6 
(with or without microsomal activation).  
Result: We would not expect compound 1 to act as a mutagen. 
TOX_MUT_Code: m4 
Summarizes output of TOX_MUT_* models from the program. Accounts for the 
compound’s metabolites.  
Results: Metabolite 4 (m4) may be a possible mutagen (TOX_Code Mut), with a 
TOX_MUT_Risk of 2 out of a 0-6 scale.  
TOX_MUT_1535: Negative 
Qualitative assessment of mutagenicity of the pure compound  in TA1535 strain 
of S. typhinmurium. 
TOX_MUT_m1535: Positive (50%) 
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Qualitative assessment of mutagenicity of the compound and its microsomal rat 
liver metabolites in TA1535 strain of S. Typhinmurium. 
TOX_Risk: 3 
Score from 0-7, indicates the number of toxicity problems a compound might 
have. An overall toxic liability score, derived from World Drug Index (this 
includes natural product structures). Score exceeds 2 for ~10% focused WDI. 
Results: This compound may present a low-moderate toxicological risk as a single 
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be 
considered. 
TOX_Code: Xr, HP, SG 
Results:  
Xr: This compound may present a risk in terms of carcinogenicity in chronic rat 
studies.  
HP: this compound may present a risk as a hepatotoxin.  
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine 
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased, 
by presence of higher ALT levels. This compound may cause elevated levels of 
ALT. 
TOX_Rat: 768.94 mg/kg/day oral dose LD50 
TOX_BRM_RAT: 1.95 mg/kg/day oral dose TD50 
Predicts the TD50 value of a particular compound in units of mg/kg/day. The 
TD50 is the dose of a substance administered orally to rats over the course of their 
lifetimes that results in the appearance of tumors in 50 percent of their population.  
TOX_BRM_MOUSE: 75.252 mg/kg/day oral dose TD50 
Similar TD50 value for mouse model. 
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TOX_CABR: Toxic (79%) 
Qualitative estimation of triggering the mutagenic chromosomal aberrations. 
TOX_REPR: Toxic (72%) 
Qualitative estimation of reproductive / developmental toxicity. 
TOX_AlkPhos: Elevated (98%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
Alkaline Phosphatase enzyme. 
TOX_GGT: Elevated  
Human liver adverse effect as the likelihood of causing elevation in the levels of 
GGT enzyme. 
TOX_SGOT: Elevated (99%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGOT enzyme. 
TOX_SGPT: Elevated (74%)  
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGPT enzyme. 
TOX_AR_Filter: Non-toxic to AR 
Qualitative assessment of the androgen receptor toxicity in rats. 
TOX_ER_Filter: Non-toxic to ER 
Qualitative assessment of the estrogen receptor toxicity in rats. 
 
Overall ADMET_Risk: 3 
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a 
computational filter developed by Simulations Plus Inc. using a refined subset of 
the WDI. 
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Overall Simulation Summary for Compound 2: 
 Compound 2 can be expected to be a substrate to CYPC19 but not to 2E1. 
CYP2C19 is important in the clearance of several classes of exceptionally widely 
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin 
and S-mephenytoin, as well as barbiturates, benzodiazapenes, SSRIs, and the 
antimalarial proguanil. Possible contraindication with use alongside PPI (protein 
pump inhibitors). Compound 2 does not appear to pose a liability to overall CYP-
function (CYP_RISK: 0).  
 Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg 
dosage/60kg-body weight/day, is below 3.16 mg/kg/day, indicating some potential 
for overall toxicity. On further inspection, however, LD50 and TD50 values are 
still quite high. LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that 
would be lethal to 50% of rats was 721.84 mg/kg/day, requiring a 43.31 gram oral 
dose for a 60kg-body weight/day. The TD50 or oral dose required to induce 
tumors in 50% of rats after exposure over a standard lifetime (TOX_BRM_Rat), 
measured in mg/kg/day oral dose, is 3.86 mg/kg/day. This would require a human 
equivalent oral dose of 231.6 mg/day of the pure compound. In mice 
(TOX_BRM_Mouse), the number is 91.36 mg/kg/day, equating to a 5.48 gram 
oral dose each day of the single compound. TOX_Code Xr indicates that this 
compound may present a risk in terms of carcinogenicity in chronic rat studies, 
because TOX_BRM_Rat is below 4 mg/kg/day oral dose. For a 60 kg body 
weight, that would amount to 240 mg/kg/day of the pure compound. The 
compound in its current formulation is so dilute as to be presumed to be safe 
because it is present in an average daily dose in concentrations well below 
concentrations cited above. 
 With an overall mutagenicity score representing the results of virtual Ames 
testing (TOX_MUT_Risk) of 1, on a score of 0-6 (with or without microsomal 
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activation), this compound is not likely to present a serious mutagenic risk. Out of 
the ten virtual Ames tests conducted, this compound flagged one: an elevated risk 
for a metabolite of the pure compound likely to cause mutagenesis in TA1535 
strain of Salmonella typhimurium (TOX_MUT_m1535). Other qualitative risk 
estimations for toxic liabilities may also elevated risk for chromosomal aberration 
(TOX_CABR) at 71%, but not a risk as a reproductive toxin (TOX_REPR) at 
80%. 
 Human liver adverse effect as the likelihood of causing elevation in the 
levels of a variety of liver enzymes, including elevated alkaline phosphatase 
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%, 
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 90%, and 
elevated SGPT enzyme at 74%. Thus, extremely concentrated doses of this 
compound may cause cardiac toxicity, chromosomal aberration, and reproductive 
toxicity. Elevation at higher doses may result in increased levels of alkaline 
phosphatase (98%), GGT (86%), LDH, SGOT (99%), and SGPT (74%) liver 
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination 
of liver enzymes levels would rise as a result of this compound, and that this 
compound could result in hepatotoxicity. Further indication of liver damage or 
disease, by the presence of higher levels of enzyme, the binary yes/no value, 
TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase 
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the 
presence of compound 2. Thus, this compound may cause increased levels of 
enzymes involved with hepatotoxicity. 
 The model does not indicate that the compound would be toxic to the 
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and 
TOX_AR_Filter). 
 With an overall ADMET_RISK composite score for all of these models, on 
a scale of 0-24, this compound scored 3. 
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BRIs present in Compound 2: 
Through CYP2C19, a potential simple Michael Acceptor is formed (metabolite 4, 
M4). This intermediate may be a possible mutagen (TOX_Code Mut), 
TOX_MUT_Risk of 3 (out of 0-6).  
 
ADMET results: 
CYP2C19 Substrate: Yes 
 CLint: 0.0145 
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism 
expressed in uL/min/mg microsomal protein. 
CYP2E1 Substrate: Non-substrate 
MET_UGT2B7: Yes, 97%.  
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 2B7 
enzyme. Responsible for conjugation of bile acids, catechol estrogens, morphine 
and naproxen, hydroxymidazolam, gemfibrozil, AZT and many other drugs. 
Midrazolam is also a substrate, and structurally similar to this compound, with 
both sharing an imidazo- ring. 
Results: Further metabolism of this molecule via glucoronidation via the UGT2B7 
enzyme is predicted. 
CYP_RISK: 0 
ADMET Code for metabolic liability - a computational filter developed by using a 
refined subset of the WDI. 
TOX_MRTD: Below 3.16 (56%) 
A qualitative assessment of the maximum recommended therapeutic dose 
administered as an oral dose in mg/kg/day. 
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TOX_MUT_Risk: 1 
Represents the results of 10 virtual Ames tests. Predicts overall mutagenicity by 
counting the number of “Positive” mutagenicity predictions. On a score of 0-6 
(with or without microsomal activation).  
Result: We would not expect compound 2 to act as a mutagen. 
TOX_MUT_Code: m4 
Summarizes output of TOX_MUT_* models from the program. Accounts for the 
compound’s metabolites.  
Results: Metabolite 4 (m4) may be a possible mutagen (TOX_Code Mut), with a 
TOX_MUT_Risk of 2 out of a 0-6 scale.  
TOX_MUT_1535: Negative 
Qualitative assessment of mutagenicity of the pure compound  in TA1535 strain 
of S. Typhinmurium. 
TOX_MUT_m1535: Positive (58%) 
Qualitative assessment of mutagenicity of the compound and its microsomal rat 
liver metabolites in TA1535 strain of S. Typhinmurium. 
TOX_Risk: 3 
Score from 0-7, indicates the number of toxicity problems a compound might 
have. An overall toxic liability score, derived from World Drug Index (this 
includes natural product structures). Score exceeds 2 for ~10% focused WDI. 
Results: This compound may present a low-moderate toxicological risk as a single 
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be 
considered. 
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TOX_Code: Xr, HP, SG 
Results:  
Xr: This compound may present a risk in terms of carcinogenicity in chronic rat 
studies.  
HP: this compound may present a risk as a hepatotoxin.  
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine 
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased, 
by presence of higher ALT levels. This compound may cause elevated levels of 
ALT. 
TOX_Rat: 721.84 mg/kg/day oral dose LD50 
TOX_BRM_RAT: 3.86 mg/kg/day oral dose TD50 
Predicts the TD50 value of a particular compound in units of mg/kg/day. The 
TD50 is the dose of a substance administered orally to rats over the course of their 
lifetimes that results in the appearance of tumors in 50 percent of their population.  
TOX_BRM_MOUSE: 91.36 mg/kg/day oral dose TD50 
Similar TD50 value for mouse model. 
TOX_CABR: Toxic (71%) 
Qualitative estimation of triggering the mutagenic chromosomal aberrations. 
TOX_REPR: Non-toxic 
Qualitative estimation of reproductive / developmental toxicity. 
TOX_AlkPhos: Elevated (98%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
Alkaline Phosphatase enzyme. 
TOX_GGT: Elevated (70%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
GGT enzyme. 
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TOX_SGOT: Elevated (90%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGOT enzyme. 
TOX_SGPT: Elevated (74%)  
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGPT enzyme. 
TOX_AR_Filter: Non-toxic to AR 
Qualitative assessment of the androgen receptor toxicity in rats. 
TOX_ER_Filter: Non-toxic to ER 
Qualitative assessment of the estrogen receptor toxicity in rats. 
 
Overall ADMET_Risk: 3 
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a 
computational filter developed by Simulations Plus Inc. using a refined subset of 
the WDI. 
  
 111 
Overall Simulation Summary for Compound 3: 
 Compound 3 can be expected to be a substrate to CYPC19 and 2E1. 
CYP2C19 is important in the clearance of several classes of exceptionally widely 
used drugs, such as the proton pump inhibitors (PPIs) like clopidogrel, phenytoin 
and S-mephenytoin, as well as barbiturates, benzodiazapenes, SSRIs, and the 
antimalarial proguanil. Possible contraindication with use of this compound 
alongside PPI (protein pump inhibitors). This compound may be a CYP2E1 
substrate (60% likelihood). Very few drugs cleared by 2E1, although it generates 
reactive oxygen species without substrate present, and are thus implicated in liver 
malfunction in alcoholics and cancer patients because of these reactive oxygen 
species. It is also likely that this compound is further metabolized through 
glucoronidation via the UGT2B7 enzyme. This enzyme is responsible for 
conjugation of bile acids, catechol estrogens, morphine and naproxen, 
hydroxymidazolam, gemfibrozil, AZT and many other drugs. Midrazolam is also 
a substrate, and structurally similar to this compound, with both sharing an 
imidazo- ring. Possible contraindication with use in alcoholics, and cancer patients 
may be advised. Compound 3 does not appear to pose a liability to overall CYP-
function (CYP_RISK: 0).  
 Maximum recommended therapeutic oral dose (TOX_MRTD), based on mg 
dosage/60kg-body weight/day, is above 3.16 mg/kg/day, indicating less potential 
for overall toxicity.  LD50 for lethal acute rat (TOX_RAT) in mg/kg oral dose that 
would be lethal to 50% of rats was 985.77 mg/kg/day, requiring a 59.15 gram oral 
dose for a 60kg-body weight/day. The TD50 or oral dose required to induce 
tumors in 50% of rats after exposure over a standard lifetime (TOX_BRM_Rat), 
measured in mg/kg/day oral dose, is 15.23 mg/kg/day. This would require a 
human equivalent oral dose of 913.8 mg/day of the pure compound. In mice 
(TOX_BRM_Mouse), the number is 38.27 mg/kg/day, equating to a 2.30 gram 
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oral dose each day of the single compound. The compound in its current 
formulation is so dilute as to be presumed to be safe. 
 With an overall mutagenicity score representing the results of virtual Ames 
testing (TOX_MUT_Risk) of 0, on a score of 0-6 (with or without microsomal 
activation), this compound is not likely to present a serious mutagenic risk. No 
risk for chromosomal aberration (TOX_CABR) at 94%, or as a reproductive toxin 
(TOX_REPR) at 75% was found. 
 Human liver adverse effect as the likelihood of causing elevation in the 
levels of a variety of liver enzymes, including elevated alkaline phosphatase 
enzyme (TOX_AlkPhos) at 98%, elevated GGT enzyme (TOX_GGT) at 86%, 
elevated LDH enzyme (TOX_LDH), elevated SGOT (TOX_SGOT) at 76%, and 
elevated SGPT enzyme at 66%. Thus, extremely concentrated doses of this 
compound may cause cardiac toxicity, chromosomal aberration, and reproductive 
toxicity. Elevation at higher doses may result in increased levels of alkaline 
phosphatase (98%), GGT (86%), LDH, SGOT (76%), and SGPT (66%) liver 
enzymes. The binary value, yes/no, TOX_Code HP indicates that a combination 
of liver enzymes levels would rise as a result of this compound, and that this 
compound could result in hepatotoxicity. Further indication of liver damage or 
disease, by the presence of higher levels of enzyme, the binary yes/no value, 
TOX_Code SG indicates increased levels in serum glutamic pyruvic transaminase 
(SGPT), now known as alanine aminotransferase (ALT) may be elevated in the 
presence of compound 3. Thus, this compound may cause increased levels of 
enzymes involved with hepatotoxicity. 
 The model does not indicate that the compound would be toxic to the 
androgen receptor or estrogen receptor in rats (TOX_AR_Filter and 
TOX_AR_Filter). 
 With an overall ADMET_RISK composite score for all of these models, on 
a scale of 0-24, this compound scored 3. 
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BRIs present in Compound 1: 
None indicated. 
ADMET results: 
CYP2C19 Substrate: Yes 
 CLint: 12.9 
Intrinsic clearance constants for predicted sites of CYP2C19 mediated metabolism 
expressed in uL/min/mg microsomal protein. 
CYP2D6 Substrate: Yes (98%) 
 CLint: 5.0 
MET_2D6_Inh: Yes 
CYP2E1 Substrate: Yes (58%) 
MET_UGT1A6: Yes, 58%.  
Qualitative model of a glucoronidation by the UDP glucuronosyltransferase 1A6 
enzyme. Metabolizes small, planar, and phenolic chemicals. 
Results: Further metabolism of this molecule via glucoronidation via the UGT1A6 
enzyme is predicted. 
CYP_RISK: 0 
ADMET Code for metabolic liability - a computational filter developed by using a 
refined subset of the WDI. 
TOX_MRTD: Above 3.16 (56%) 
A qualitative assessment of the maximum recommended therapeutic dose 
administered as an oral dose in mg/kg/day. 
TOX_MUT_Risk: 0 
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Represents the results of 10 virtual Ames tests. Predicts overall mutagenicity by 
counting the number of “Positive” mutagenicity predictions. On a score of 0-6 
(with or without microsomal activation).  
Result: We would not expect compound 3 to act as a mutagen. 
TOX_Risk: 2 
Score from 0-7, indicates the number of toxicity problems a compound might 
have. An overall toxic liability score, derived from World Drug Index (this 
includes natural product structures). Score exceeds 2 for ~10% focused WDI. 
Results: This compound may present a low-moderate toxicological risk as a single 
chemical entity. Dosing, formulation, and carrier vehicle chemistry should be 
considered. 
TOX_Code: HD, HP, SG 
Results:  
HD: This compound possesses hydrogen bond donors.  
HP: this compound may present a risk as a hepatotoxin.  
SG: serum glutamic pyruvic transaminase (SGPT), now known as alanine 
aminotransferase (ALT) test. Measured to see if the liver is damaged or diseased, 
by presence of higher ALT levels. This compound may cause elevated levels of 
ALT. 
TOX_Rat: 985.77 mg/kg/day oral dose LD50 
TOX_BRM_RAT: 15.23 mg/kg/day oral dose TD50 
Predicts the TD50 value of a particular compound in units of mg/kg/day. The 
TD50 is the dose of a substance administered orally to rats over the course of their 
lifetimes that results in the appearance of tumors in 50 percent of their population.  
TOX_BRM_MOUSE: 38.27 mg/kg/day oral dose TD50 
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Similar TD50 value for mouse model. 
TOX_CABR: Toxic (71%) 
Qualitative estimation of triggering the mutagenic chromosomal aberrations. 
TOX_REPR: Non-toxic 
Qualitative estimation of reproductive / developmental toxicity. 
TOX_AlkPhos: Elevated (98%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
Alkaline Phosphatase enzyme. 
TOX_GGT: Elevated (70%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
GGT enzyme. 
TOX_SGOT: Elevated (90%) 
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGOT enzyme. 
TOX_SGPT: Elevated (74%)  
Human liver adverse effect as the likelihood of causing elevation in the levels of 
SGPT enzyme. 
TOX_AR_Filter: Non-toxic to AR 
Qualitative assessment of the androgen receptor toxicity in rats. 
TOX_ER_Filter: Non-toxic to ER 
Qualitative assessment of the estrogen receptor toxicity in rats. 
 
Overall ADMET_Risk: 3 
On a scale of 0-24. Summarizes all other ADMET Risk/Code models - a 
computational filter developed by Simulations Plus Inc. using a refined subset of 
the WDI. 
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Conclusions 
 Phytochemicals isolated from Iresine celosia and their CYP450-produced 
biological metabolites were screened for their potential toxicity using the ADMET 
predictor proprietary software, a modeling tool from Simulations Plus. The 
software was also used to predict metabolites formed from chemical structures 
within the body, to analyze whether these structures are likely to go on to cause 
toxicity, and to determine the ability of these compounds to interfere with other 
drug substances, by way of their ability to inhibit Cytochrome P450 (CYP) drug 
metabolizing enzymes. 
 ADMET Predictor proved capable of predicting CYP sites of metabolism. 
ADMET Predictor was found unable to handle Michael addition reactions 
(including when these reactions were CYP mediated). ADMET Predictor unable 
to handle epoxides or arene oxides, because of the extremely brief and fleeting 
nature of these compounds, but it was correctly predict oxidation of phenyl ring at 
para position, which is the result of an epoxide-forming reaction. Most O- and N-
dealkylations were also correctly predicted from test studies. Overall, the program 
accomplished what it sets out to do: to cover the most commonly observed 
potential sites of oxidation. 
 Based on the information obtained from in silico screening of compounds 
isolated from Iresine celosia formulation, a reasonable expectation of safety is 
warranted when using this preparation as directed.  
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Conclusion 
Through a comprehensive phytochemical evaluation, phytochemical 
compounds present within the Odyliresin™ formulation have been isolated, and 
identified using a variety of chromatographic and spectroscopic techniques, 
including HR-MS, NMR, HPLC-UV, FT-IR and CD spectroscopy. Unique 
botanical marker compounds have been identified, which allows for authentication 
of the identity of the botanical and standardization of the formulation extract. 
Methods have been developed to isolate these compounds, and fingerprint profiles 
generated to characterize the extract. These compounds are structurally rare within 
the plant kingdom, and contain stereochemical complexity that derivatization and 
crystallization methods have failed to resolve. At present, we are using electronic 
circular dichroism (E-CD) and computer simulations to attempt to resolve the 
three stereocenters, with a total of 8 possible overall conformations.  
 Biological activity of these compounds has been screened using in silico 
docking experiments with the human androgen receptor (AR), prostate-cancer 
relevant mutant types and wild type varieties. This preliminary information 
supported further testing in vitro and the marker compounds did, in fact, prove 
active on the 12.5 to 50 µM range. This data suggests that I. celosia may have 
implications in promoting prostate health. Additional testing of the compound for 
mechanism of action studies could be interesting. Based on comparable in silico 
docking results as EGCG and aristolochic acid, known antiandrogens, it is 
possible that these compounds may also work to competitively inhibit the binding 
of testosterone to the AR. However, further testing through receptor based 
competitive inhibition assays would be necessary. 
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 These compounds were also screened for biological activity and reactivity, 
based on the presence of natural product specific biologically reactive 
intermediates. The compounds were further screened in silico using proprietary 
computational toxicology software, Simulations Plus. Sites of metabolism and 
CYP-inhibition were considered, as were mutagenicity, implications adverse liver 
function, and general dosing, among other considerations. Guanidine alkaloid 
compounds 1, 2, and even 3 are metabolized primarily by the CYP2C19, however, 
CYP219, 2E1 and 2D6 may also play a role in their clearance from the body. 
Phase II glucoronidation of these compounds is also likely, with UGT2B7 also 
becoming involved. Predicted metabolites were also screened for their reactivity. 
Further animal studies could be useful to confirm LD50 and TD50 values derived 
from computational simulation, in either rat or mouse. However, it is likely that 
the toxicity arising from the use of these individual compounds within 
concentrated doses of the extract is quite low. Therefore, animal studies conducted 
on a small scale and in one species may be sufficient to obtain the confirmatory 
information needed. Overall, a generalized evaluation of the safety and risk profile 
of the botanical’s individual compounds was obtained, from which can be 
extrapolated a low level of risk when using this product as directed. 
It is important to keep in mind that the formulation is not comprised solely of 
active principles, but that the formulation is a plant extract containing a variety of 
compounds, but health relevant and those that may be irrelevant. Similarly, the 
cell testing assays we conduct and docking simulations are simplified models that 
consider the individual structures themselves. Only by considering the totality of 
this information can we approximate the possible biological activity of the 
formulation in total. The study of complex botanical materials is its own 
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discipline, and attempts to find isolable principles and standardize these extracts 
currently represents the most useful strategy toward understanding their activity in 
humans. The natural variety inherent in preparations, in growing conditions, in 
species evolution from a chemocentric perspective, the complex matrix in which 
what are thought to be active principles are delivered to the body is often 
discounted, and can present challenges to the standardization of such preparations. 
Based on HPLC standardization of the Odyliresin™ formulation of Iresine 
celosia, it’s difficult to assess whether these compounds would be present in 
enough quantity to affect a health outcome. However, synergistic effects of 
compounds within the extract may play a role in its biological activity. Such 
information could not be obtained from computational toxicology studies at this 
time, and in such a case, the thoughtful conduct of animal studies may prove 
helpful in further elucidating the formulation’s modes of action. 
Chemistry is the key to understanding natural products, and considering 
whether herbal medicines “work” and whether or not they are safe. At present, the 
advances in chemistry have far outpaced the development of clinical 
pharmacology and toxicology to understand the working of complex botanical 
mixtures. Because definitive pharmacological and toxicological results are hard to 
come by with respect to herbal medicines, some take this to mean that herbals 
have no actual health effect, and therefore no basis in therapy from a scientific 
perspective. Nevertheless, people continue to buy, ingest, and use herbal products. 
Chemistry present in herbal products becomes part of the larger biochemical 
milieu of items people ingest and substances to which people are exposed, which 
also includes food, water, and alcohol, too. Because this complex milieu is 
difficult to study, and at present only being tackled in the realm of systems 
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pharmacology; because chemistry is by far the most advanced scientific 
expression of ethnopharmacology  — it seems reasonable to leverage what we 
know to be true about the chemistry and bioactivity/bioreactivity profile of these 
compounds and use it to consider compounds for which information is lacking, 
and distinguish thresholds of concern that may warrant further testing to ensure a 
reasonable expectation of safety. 
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Supporting Information Available 
For Compound 1 
Figure S1. 1H NMR spectrum of Compound (1) in (CD3)2S=O 
Figure S2. 13C NMR spectrum of Compound (1) in (CD3)2S=O 
Figure S3. COSY correlations of Compound (1) in (CD3)2S=O 
Figure S4. COSY spectrum of Compound (1) in (CD3)2S=O 
Figure S5: HSQC spectrum of Compound (1) in (CD3)2S=O 
Figure S6: HMBC correlations (H -> C) for Compound (1) in (CD3)2S=O 
Figure S7: HMBC spectrum (H -> C) of Compound (1),in (CD3)2S=O, 
unexchanged 
Figure S8: HMBC spectrum (H ->C) of Compound (1), proton exchanged with 
D2O 
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Figure S9. NOESY correlations of Compound (1) in (CD3)2S=O 
Fig. S10. NOESY spectrum of Compound  (1) in (CD3)2S=O 
Fig. S11. NOESY spectrum of  (1) in (CD3)2S=O, with irradiated proton at 3.82 
ppm 
Fig. S12. NOESY spectrum of (1) in (CD3)2S=O, with irradiated proton at 3.46 
ppm 
Figure S13. 1H NMR spectrum of Compound (1) in (CD3)2S=O, unexchanged 
Figure S14. 1H NMR spectrum of Compound (1) in (CD3)2S=O, exchanged with 
D2O 
 
For Compound 2 
Figure S1. 1H NMR spectrum of Compound (2) in (CD3)2S=O 
Figure S2. 1H NMR spectrum of Compound (2) in (CD3OD) 
Figure S3. COSY correlations of Compound (2) in (CD3)2S=O 
Figure S4. COSY spectrum of Compound (2) in (CD3)2S=O 
Figure S5. 13C NMR spectrum of Compound (2) in (CD3)2S=O 
Figure S6: HSQC spectrum of Compound (2) in (CD3)2S=O 
Figure S7: HMBC correlations (H -> C) of Compound (2) in (CD3)2S=O 
Figure S8: HMBC spectrum (H -> C) of Compound (2) in (CD3)2S=O 
Figure S9. 1H NMR spectrum of Compound (2) in (CD3)2S=O, unexchanged 
Figure S10. 1H NMR spectrum of Compound (2) in (CD3)2S=O, exchanged with 
D2O  
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Figure 5: Isolation scheme for Iresine celosia 
 
  
Iresine celosia aerial material (2000 g)
Extracted with 30% ethanol, 16 L
9 L collected; dried to 1.2 mL
Extracted with n-Hexane
n-Hexane-soluble fraction (0.4 g) Aqueous layer
Extracted with 
EtoAC
Aqueous layerEtOAc-soluble fraction (3 g viscous)
Extracted with 
n-BuOH
H2O-soluble fractionn-BuOH-soluble fraction (8.93 g)
Silica Gel CC
5.5 g
CHCl3 and MeOH
Fraction A 
(0.85 g)
Fraction B-D 
(0.84 g)
Fraction E 
(1.2 g)
Fraction F 
(2.8 g)
Sephadex LH-20
(0.8 g)
MeOH
20E 
(0.113 g)
20 A-D
(0.56 g)
Compound 7, 8, 9, 11
(3.5, 13, 3.2, 3 mg)
Semi-preparative 
HPLC
20F 
(0.060 g)
Compound 4, 10
(0.7, 1.8 mg)
20G 
(0.038 g)
Compound 5, 6
(2.8, 2.8 mg)
24A
(0.37 g)
24B
(0.3 g)
Semi-preparative
HPLC
Compound 1, 2, 3
(25, 5.7, 2.3 mg)
Sephadex LH-20
(1g)
MeOH
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Figure 6. 1H NMR spectrum of Compound (1) in (CD3)2S=O, unexchanged  
  
 
 
 
Figure 7. 1H NMR spectrum (1) in (CD3)2S=O, exchanged with D2O  
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Figure 8. COSY correlations of Compound (1) in (CD3)2S=O  
 
  
 
 
 
Figure 9. COSY spectrum of Compound (1) in (CD3)2S=O  
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Figure 10. 13C NMR spectrum of Compound (1) in (CD3)2S=O 
 
  
 
 
 
 
Figure 11. HSQC spectrum of Compound (1) in (CD3)2S=O  
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Figure 12. HMBC correlations (H -> C) for Compound (1) in (CD3)2S=O 
 
 
 
 
 
 
 
Figure 13: HMBC spectrum (H -> C) for Compound (1),  in (CD3)2S=O, unexchanged 
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Figure 14: HMBC spectrum (H ->C) for Compound (1), proton exchanged with 
D2O 
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Figure 15. Key NOESY correlations of Compound (1) in (CD3)2S=O  
 
  
 
 
 
 
Figure 16. NOESY spectrum of Compound (1) in (CD3)2S=O  
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Figure 17. NOESY Spectrum of Compound (1) in (CD3)2S=O,  with irradiated proton at 3.82ppm 
 
 
  
 
 
 
Figure 18. NOESY spectrum of Compound (1) in (CD3)2S=O,  with irradiated proton at 3.46 ppm 
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Figure 19: IR Spectrum of Compound (1) 
 
 
 
 
 
 
Figure 20: MS Spectrum for Compound (1) 
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Table 5. Spectral Assignments for Compound (2) 
 
 
Position δ C (mult.) δ H (mult., J in 
Hz) 
COSY HMBC  
1 18.17, 3H 1.73, s H-4 C-5, C-3, C-2 
2 138.45   H-5, H-4, H-1 
3 117.42    H-5, H-4, H-1 
4 41.87, 2H 3.95, dd (7.1) H-6, H-1 C-3, C-2, C-4’, C-4” 
5 25.86, 3H 1.79, s H-4 C-3, C-2, C-1 
6  5.18, t (7.1) H-4 C-5, C-1 
3' 2H 8.05, s   
4' 159.14   H-4, H-4” 
1" 12.87, 3H 1.14, d (7.1) H-2” C-5”, C-3”, C-2” 
2" 43.73, 1H 2.56, m H-3”, H-1” C-5”. C-3”, C-1” 
3" 54.53, 1H 4.11, m (10.1, 6.3) H-4”, H-2” C-5”, C-4”, C-1” 
4" 50.88, 2H 3.72, dd (10.1) H-4”, H-3” C-3”, C-2” 
  3.36, dd (10.1, 6.3) H-4”, H-3” C-3”, C-2” 
5” 175.59   H-2”, H-1” 
6" 1H 12.69, s   
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Figure 21. 1H NMR spectrum of Compound (2) in (CD3)2S=O, unexchanged 
 
  
 
 
 
Figure 22. 1H NMR spectrum of Compound (2) in (CD3)2S=O, exchanged with D2O  
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Figure 23. Key 1H -> 1H COSY correlations of Compound (2) in (CD3)2S=O  
 
 
  
 
 
 
 
Figure 24. COSY spectrum of Compound (2) in (CD3)2S=O  
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Figure 25. 13C NMR spectrum of Compound (2) in (CD3)2S=O  
 
  
 
 
 
Figure 26: HSQC spectrum of Compound (2) in (CD3)2S=O  
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Figure 27: HMBC correlations (H -> C) for Compound (2) in (CD3)2S=O  
 
 
 
 
 
Figure 28: HMBC spectrum (H -> C) for Compound (2) in (CD3)2S=O  
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Figure 29: IR spectrum of Compound (2) 
 
 
 
 
 
 
 
Figure 30: MS Spectrum for Compound (2) 
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Table 6. Spectral Assignments for Compound (3), 
Hydroxygalegine 
 
 
Position δ C (mult.) δ H (mult., J in Hz) COSY HMBC  
2 156.34   H-5 
5 45.5, 2H 4.09, d (7.1) H-10, H-6  
6 119.52, 1H 5.31, t (7.1) H-10, H-5 H-8, H-5. H-10 
7 140.28   H-8, H-5. H-10 
8 60.53, 2H 4.12, s  H-6, H-10 
10 20.97, 3H 1.81, s H-6, H-5 H-6, H-8 
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Figure 31. 1H spectrum of Compound (3) in CD3OD 
 
 
 
 
 
 
 
Figure 32. 13C spectrum of Compound (3) in CD3OD 
 
 
 141 
 
Figure 33. COSY spectrum of Compound (3) in CD3OD 
 
 
 
 
 
 
 
Figure 34. HMBC spectrum of Compound (3) in CD3OD 
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Figure 35. HSQC spectrum of Compound (3) in CD3OD 
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Table 7. Ligand Binding Affinities for Control Structures with 
WT and Mutant Androgen Receptors 
 
PBD ID# Ligand affinity 
kcal/mol 
rmsd l.b. Dist from best mode, 
rmsd u.b. 
2YHD testosterone -11.2 0 0 
  -8.9 1.472 6.158 
  -8.4 1.214 6.579 
1I37  -11.2 0 0 
  -9.3 1.148 6.536 
  -8.3 1.477 2.715 
2Q7K  -11.8 0 0 
2YHD dihydrotestosterone -10.2 0 0 
  -9.4 1.529 2.897 
  -9.4 1.145 6.123 
1I37  -10.9 0 0 
  -9.5 1.110 6.095 
  -9.2 1.273 2.573 
2Q7K  -11.3 0 0 
  -10.1 1.150 6.093 
  -9.9 1.180 2.544 
2YHD stigmasterol -1.7 0 0 
  -1.5 2.781 7.429 
  -0.3 1.577 3.298 
1I37  -1.6 0 0 
  -1.5 2.782 7.433 
  -0.3 2.838 7.497 
2Q7K  -1.9 0 0 
  -1.4 2.795 8.079 
  -0.8 0.890 2.486 
2YHD betasitosterol -2.3 0 0 
  -1.1 2.796 7.498 
  -0.5 2.777 7.364 
1I37  -0.1 0 0 
  -2.8 1.228 2.848 
2Q7K  -0.5 0 0 
  -1.2 2.881 7.442 
  -1.2 2.792 7.508 
2YHD atraric acid -6.1 0 0 
  -5.9 1.547 1.859 
  -5.8 2.259 5.216 
1I37  -6.3 0 0 
  -5.9 2.232 3.037 
  -5.9 1.983 5.014 
2Q7K  -6.8 0 0 
  -6.7 0.665 1.158 
  -6.2 1.905 5.012 
2YHD EGCG -6.8 0 0 
  -6.8 0.014 1.443 
1I37  -4.2 0 0 
  -4.1 0.005 1.443 
2Q7K  -6.0 0 0 
  -6.0 0.030 1.443 
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Table 8. Ligand Binding Affinities for I. celosia Structures with 
WT and Mutant Androgen Receptors 
PBD 
ID# 
Ligand affinity kcal/mol rmsd 
l.b. 
Dist from best mode, 
rmsd u.b. 
2YHD compound 1 -6.6 0 0 
  -6.5 2.251 5.559 
  -6.4 2.147 5.984 
1I37  -6.8 0 0 
  -6.8 1.507 1.875 
  -6.6 1.947 6.062 
2Q7K  -7.1 0 0 
  -7.0 2.195 5.709 
  -7.0 1.409 1.851 
2YHD compound 2 -6.8 0 0 
  -6.8 3.537 5.840 
  -6.6 3.611 5.954 
1I37  -6.7 0 0 
  -6.7 1.703 2.434 
  -6.6 1.386 1.847 
2Q7K  -7.1 0 0 
  -7.0 3.599 5.995 
  -7.0 3.234 5.757 
2YHD hydroxygalegine -5.1 0 0 
  -5.0 0.993 1.156 
  -4.8 3.163 4.828 
1I37  -5.3 0 0 
  -5.2 1.052 1.527 
  -4.9 3.516 4.812 
2Q7K  -5.5 0 0 
  -5.4 1.279 1.747 
  -5.2 3.479 4.904 
2YHD tlatancuayin -7.3 0 0 
  -6.1 1.739 7.080 
  -6.0 1.612 7.120 
1I37  -6.3 0 0 
  -5.7 1.792 6.695 
  -5.7 1.215 2.555 
2Q7K  -6.7 0 0 
  -6.4 1.813 7.315 
  -6.1 1.622 7.087 
2YHD drimane 2b -7.3 0 0 
  -7.2 1.389 5.513 
  -7.1 1.364 5.244 
1I37  -7.2 0 0 
  -6.9 1.292 5.490 
  -6.9 1.488 3.227 
2Q7K  -7.6 0 0 
  -7.6 1.375 5.516 
  -7.3 1.353 3.00 
2YHD drimane 3 -8.5 0 0 
  -8.1 1.575 5.636 
  -8.1 1.708 5.957 
1I37  -8.4 0 0 
  -8.4 1.643 5.424 
  -8.2 1.542 5.643 
2Q7K  -9.0 0 0 
  -9.0 1.534 5.641 
  -8.7 1.622 5.463 
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Table 9. Ligand Binding Affinities for Natural Product Structures 
Associated with Prostate Health with WT and Mutant ARs 
PBD ID# Ligand affinity kcal/mol rmsd 
l.b. 
Dist from best mode, 
rmsd u.b. 
2YHD apigenin -8.6 0 0 
  -8.2 2.102 3.740 
  -8.1 2.037 6.748 
1I37  -7.5 0 0 
  -7.4 0.124 1.076 
  -7.3 1.995 6.568 
2Q7K  -9.1 0 0 
  -9.0 0.032 1.074 
  -8.8 2.091 3.658 
2YHD baicalein -8.4 0 0 
  -7.8 2.522 6.121 
  -7.5 2.540 6.505 
1I37  -8.0 0 0 
  -7.9 2.337 6.491 
  -6.5 1.723 3.319 
2Q7K  -8.6 0 0 
  -8.6 0.019 1.074 
  -8.5 1.878 3.391 
2YHD emodin -8.7 0 0 
  -8.4 1.348 5.535 
  -8.4 1.192 1.347 
1I37  -8.2 0 0 
  -8.0 1.473 5.560 
  -6.8 1.116 3.221 
2Q7K  -9.1 0 0 
  -8.9 1.501 5.572 
  -8.9 1.150 3.306 
2YHD genistein -9.2 0 0 
  -9.1 1.148 6.884 
  -9.1 1.137 6.806 
1I37  -9.3 0 0 
  -8.8 1.469 6.965 
  -8.3 1.546 7.143 
2Q7K  -10.1 0 0 
  -9.6 1.183 6.882 
  -9.4 1.272 6.819 
2YHD icaritin -7.7 0 0 
  -7.2 1.365 1.720 
  -5.7 2.073 7.059 
1I37  -6.9 0 0 
  -5.3 2.004 7.105 
  -5.2 1.503 2.078 
2Q7K  -7.2 0 0 
  -6.1 1.457 1.930 
  -5.7 2.025 7.057 
2YHD xanthohumol -5.8 0 0 
  -5.7 1.420 3.829 
  -5.4 1.925 7.397 
1I37  -2.9 0 0 
  -2.9 2.038 3.288 
  -2.8 12.33 14.592 
2Q7K  -3.7 0 0 
  -3.7 1.717 4.113 
  -3.6 1.040 1.580 
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Butanol Extract 
 
 
 
 
Figure 36: In vitro prostate cancer cell screening of lab-
generated butanol extract against AR-positive LNCaP and AR-
negative PC3 cells 
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Compound 1 
 
Figure 37: In vitro prostate cancer cell screening of Compound 
(1) against AR-positive LNCaP and AR-negative PC3 cells 
 
 
 
 
Compound 2 
 
Figure 38: In vitro prostate cancer cell screening of Compound 
(2) against AR-positive LNCaP and AR-negative PC3 cells 
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Figure 39: Ethyl acetate (bottom) fraction from 30% ethanol extract of 
Iresine celosia overlaps strongly with the butanol partition (top) 
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Fig. 40: Procedure for the determination of compounds in lab-
generated Iresine celosia extract and manufacturer’s 
Odyliresin™ formulation 
 
 
 
 
  
HPLC-DAD
n-Butanol layer
Liquid-liquid partition
Lab-generated Formulation
•  Dried using in vacuo
•  Reconstituted in 30% HPLC-grade 
methanol and DI water
•  Added 10 mL n-hexanes
•  Shook vigorously and let settle for 10 min.
•  Collected water layer
•  Repeated above steps 3x
•  Repeated entire procedure with ethyl 
acetate, and then n-butanol 
•  16L 30% ethanol added to 2K aerial 
I. celosia plant material
•  9L ethanolic extract recovered and 
evaporated in vacuo to 4.5 mL
HPLC-DAD
n-Butanol layer
Liquid-liquid partition
15 mL of Odyliresin Formulation
•  Dried in vacuo
•  Reconstituted in 30% HPLC-grade 
methanol and DI water
•  Added 10 mL n-hexanes
•  Shook vigorously and let settle for 10 min.
•  Collected water layer
•  Repeated above steps 3x
•  Repeated entire procedure with ethyl 
acetate, and then n-butanol 
•  Ethanol evaporated in vacuo to 10 mL
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Table 10: Characteristics of the compounds isolated from 
the Iresine celosia lab formulation’s butanol extract (Lab-
bu) 
 
 Compound Name MW peak(s) 
nm 
Rt 
(min) 
1 Compound 1 241.29 212 17.7 
2 Compound 2 225.29 212 25.4 
3 Hydroxygalegine 143.19 210 19 
4 Uracil 112.09 256 21.5 
5 Adenine 135.13 210, 260 5.6 
6 3-indole-carboxyllic 
acid 
161.16 212, 282 30 
7 2‘deoxy-uridine 228.20 210, 260 8.3 
8 2‘deoxy-thymidine 242.23 264 11.8 
9 2‘deoxy-5'-O-methyl-
uridine 
242.23 210, 260 14.8 
10 4-methoxy-benzoic 
acid (anisic acid) 
152.15 260 23.3 
11 Phenylacetamide 135.07 212 30.2 
 
 
 
Table 11: Calibration curve data for selected compounds 
isolated from the Iresine celosia lab formulation’s butanol 
extract (Lab-bu) 
 
 
Compound Rt (min) Slope (+SD)  r^2  
LOD 
(mg/mL) 
LOQ 
(mg/mL) 
1 17.7 21.3 x 10^7 (+ 8)  0.99  0.13 0.39 
2 25.4 4.4 x 10^7 (+ 1.7)  0.99  0.18 0.57 
3 19 3.3 x 10^7  0.99    
4 21.5 4.3 x 10^7  0.99    
8 11.8 19.5 x 10^7  0.99    
10 23.3 14 x 10^7  0.99    
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Figure 41: Lab n-butanol (Lab-bu) extract at 212 nm 
 
 
 
 
 
 
 
  
 
Figure 42: HPLC-UV chromatograms of Iresine celosia 30% ethanol 
extracts (D, F) and their butanol partitions (A, B, C, E) at various 
concentrations showing the presence of compounds (1-11) 
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Figure 43: Compounds (1), (2), (3) retention times  
compared with Lab-bu formulation (50 mg/mL) 
  
Lab-bu 
1
2
3
 153 
 
 
 
 
 
 
 
 
 
Figure 44: Compounds (4), (8), (10) retention times  
compared with Lab-bu formulation (50 mg/mL) 
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Fig. 45: Calibration Curves for Compound (1) at concentrations 
0.0626 to 1.0 mg/mL 
 
 
 
 
 
 
 
Fig. 46: Calibration Curves for Compound (2) at concentrations 
0.0626 to 1 mg/mL 
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Fig. 47: Calibration Curves for Compounds (3) at various 
concentrations 
 
 
 
 
 
 
 
Fig. 48: Calibration Curves for Compounds (4) at various 
concentrations 
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Fig. 49: Calibration Curves for Compounds (8) at various 
concentrations 
 
 
 
 
 
 
 
Fig. 50: Calibration Curves for Compounds (10) at various 
concentrations 
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Fig. 51: Calibration curve for presence of Compound (1) in Lab-bu 
formulation 
 
 
 
 
  
 
Fig. 52: Calibration curve for presence of Compound (2) in Lab-bu 
formulation 
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Table 12: Calibration curve data for presence of Compound 
(1) in Lab-bu formulation 
 
Formulation 
Conc. C1 (mAU) 
Compound Conc. 
y = 213,227,870.70x + 
31,411,604.31 STDEV 
RSD
% 
25  24,095,597    75,927  0.3 
50  35,298,368  0.018  177,776  0.5 
75  48,057,725  0.078  146,607  0.3 
150  93,947,009  0.293  50,742  0.1 
100  77,316,453  0.215   
500  114,027,640  0.387   
 
 
 
 
 
 
 
Table 13: Calibration curve data for presence of Compound 
(2) in Lab-bu formulation 
 
 
Formulation 
Conc. C2 (mAU) 
Compound Conc. 
y = 44,367,064.37x 
+ 12,035,158.63 STDEV 
RSD
% 
25  15,861,869  0.086  33,011  0.2 
50  22,053,873  0.226  2,788,877  12.6 
75  36,997,866  0.563  4,930,550  13.3 
100  47,774,367  0.806  10,840,923  15.4 
150  71,661,551  1.344  2,871,870  4 
500  108,202,498  2.168   
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Fig. 53: Calibration curve for presence of Compound (3) in Lab-bu formulation 
(single run) 
 
 
 
 
 
  
 
Fig. 54: Calibration curve for presence of Compounds (4) in Lab-bu formulation 
(single run) 
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Fig. 55: Calibration curve for presence of Compound (8) in Lab-bu formulation 
(single run) 
 
 
 
 
 
  
 
Fig. 56: Calibration curve for presence of Compound (10) in Lab-bu formulation 
(single run) 
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Fig. 57: Calibration curve for presence of Compound (1) 
in Odyli-bu formulation 
 
 
 
 
Fig. 58: Calibration curve for presence of Compound (2) 
in Odyli-bu formulation 
  
 162 
Table 14: Calibration curve data for presence of Compound 
(3) in Lab-bu formulation 
Conc. C3  
y = 32,909,431.43x + 
34,707,557.30 STDEV RSD% 
25  13,658,054  
 
 150,840  1.1 
50  19,351,673  
 
 560,898  2.9 
75  25,341,316  
 
 14,069  0.001 
100  29,427,093  
 
 0 0 
150  44,140,639  0.287  373,174  0.8 
500  72,696,509  1.154  0 0 
 
 
Table 15: Calibration curve data for presence of Compound 
(4) in Lab-bu formulation 
Conc. C4 
y = 43,120,226.10x + 
4,947,652.33 STDEV RSD% 
25  6,264,923  0.031  20,434  0.3 
50  11,605,373  0.154  81,082  0.7 
75  17,337,917  0.287  204,982  1.2 
150  33,534,116  0.663  192,108  0.6 
 
 
Table 16: Calibration curve data for presence of Compound 
(8) in Lab-bu formulation 
Conc. C8 
y = 194,620,399.2110x + 
2,097,490.6430 STDEV RSD% 
25  4,107,492  0.010  17,233  0.4  
50  7,693,548  0.029  43,770  0.6 
75  12,376,112  0.053  737,959  6.0 
150  25,671,359  0.12  36,678  0.1 
 
Table 17: Calibration curve data for presence of Compound 
(10) in Lab-bu formulation 
Conc. C10 
y = 140,436,619.22x + 
12,351,658.00 STDEV RSD% 
25  6,198,365  
 
 14,135  0.2 
50  11,484,942  
 
 6,638  0.1 
75  17,255,272  0.035  446,842  2.6 
150  34,207,895  0.16  191,226  0.6 
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Table 18: Calibration curve data for presence of Compound (1) in 
Odyli-bu formulation 
 
Formul. 
Conc. C1 
Compound Conc. 
y = 44,367,064.37x + 
12,035,158.63 
STDEV RSD% 
75  8,247,406    445,954  3.3 
100  11,330,014   7,101  0.05 
150  13,750,423    130,586  0.9 
250  19,109,994    752,666  3.8 
500  34,830,045  0.016  1,046,853  4.6 
 
 
Table 19: Calibration curve data for presence of Compound (2) in 
Odyli-bu formulation 
 
Formul. 
Conc. C2 
Compound Conc. 
y = 44,367,064.37x + 
12,035,158.63 
STDEV RSD% 
50  13,671,820  0.037  445,954  3.3 
75  14,385,347  0.053  7,101  0.05 
100  14,818,083  0.063  130,586  0.9 
250  19,865,699  0.176  752,666  3.8 
500  21,833,592  0.221  1,046,853  4.6 
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Figure 60: Prediction of toxicity outcomes for the following 
categories based on chemical structure 
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Figure 61: Predicted sites of metabolism for Compound 1 
 
 
 
 
 
Figure 62: Predicted metabolites for Compound 1 
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Figure 63: Predicted sites of metabolism for Compound 2 
 
 
Figure 64: Predicted metabolites for Compound 2 
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Figure 65: Predicted metabolites for Compound 3 
 
 
 
 
 
 
